

## APPROPRIATE USE OF ECHOCARDIOGRAPHY

# ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/ SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography

A REPORT OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION APPROPRIATE USE CRITERIA TASK FORCE, AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, AMERICAN HEART ASSOCIATION, AMERICAN SOCIETY OF NUCLEAR CARDIOLOGY, HEART FAILURE SOCIETY OF AMERICA, HEART RHYTHM SOCIETY, SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS, SOCIETY OF CRITICAL CARE MEDICINE, SOCIETY OF CARDIOVASCULAR COMPUTED TOMOGRAPHY, SOCIETY FOR CARDIOVASCULAR MAGNETIC RESONANCE AMERICAN COLLEGE OF CHEST PHYSICIANS

---

(J Am Soc Echocardiogr 2011;24:229-67.)

**Keywords:** ACCF Appropriate Use Criteria, Cardiac imaging, Coronary artery disease, Diagnostic testing, Echocardiography

---

### ECHOCARDIOGRAPHY WRITING GROUP

---

Pamela S. Douglas, MD, MACC, FAHA, FASE, *Chair\**  
Mario J. Garcia, MD, FACC, FACPT  
David E. Haines, MD, FACC, FHRS‡  
Wyman W. Lai, MD, MPH, FACC, FASE§  
Warren J. Manning, MD, FACC||¶  
Ayan R. Patel, MD, FACC#  
Michael H. Picard, MD, FACC, FASE, FAHA§  
Donna M. Polk, MD, MPH, FACC, FASE, FASNC\*\*  
Michael Ragosta, MD, FACC, FSCAI††  
R. Parker Ward, MD, FACC, FASE, FASNC§  
Rory B. Weiner, MD\*  
\*Official American College of Cardiology Foundation Representative; †Official Society of Cardiovascular Computed Tomography Representative; ‡Official Heart Rhythm Society Representative; §Official American Society of Echocardiography Representative; ||Official American Heart Association Representative; ¶Official Society for Cardiovascular Magnetic Resonance Representative; #Official Heart Failure Society of America Representative; \*\*Official American Society of Nuclear Cardiology Representative; ††Official Society for Cardiovascular Angiography and Interventions Representative.

---

This document was approved by the American College of Cardiology Foundation Board of Trustees in November 2010.

The American College of Cardiology Foundation requests that this document be cited as follows: Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, Picard MH, Polk DM, Ragosta M, Ward RP, Weiner RB. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2010; published online before print November 19, 2010, doi:10.1016/j.jacc.2010.11.002.

### TECHNICAL PANEL

---

Steven R. Bailey, MD, FACC, FSCAI, FAHA, *Moderator*  
Rory B. Weiner, MD, *Writing Group Liaison*  
Peter Alagona, Jr, MD, FACC\*  
Jeffrey L. Anderson, MD, FACC, FAHA, MACP\*||  
Jeanne M. DeCara, MD, FACC, FASE§  
Rowena J. Dolor, MD, MHS  
Reza Fazel, MD, FACC\*\*  
John A. Gillespie, MD, FACC##  
Paul A. Heidenreich, MD, FACC#  
Luci K. Leykum, MD, MBA, MSc  
Joseph E. Marine, MD, FACC, FHRS‡  
Gregory J. Mishkel, MD, FACC, FSCAI, FRCPC††  
Patricia A. Pellikka, MD, FACC, FAHA, FACP, FASE§  
Gilbert L. Raff, MD, FACC, FSCCT†  
Krishnaswami Vijayaraghavan, MD, FACC, FCCP§§  
Neil J. Weissman, MD, FACC, FAHA\*  
Katherine C. Wu, MD¶  
##Official Health Plan Representative; §§Official American College of Chest Physicians Representative.

---

This article is copublished in the *Journal of the American College of Cardiology* and the *Journal of Cardiovascular Computed Tomography*.

Copies: This document is available on the World Wide Web site of the American College of Cardiology ([www.cardiosource.org](http://www.cardiosource.org)). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail [reprints@elsevier.com](mailto:reprints@elsevier.com).

Permissions: Modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier's permission department [healthpermissions@elsevier.com](mailto:healthpermissions@elsevier.com).

0894-7317/\$36.00

Copyright 2011 by the American College of Cardiology.

doi:10.1016/j.echo.2010.12.008

**APPROPRIATE USE CRITERIA TASK FORCE**

Michael J. Wolk, MD, MACC, *Chair*  
 Steven R. Bailey, MD, FACC, FSCAI, FAHA  
 Pamela S. Douglas, MD, MACC, FAHA, FASE  
 Robert C. Hendel, MD, FACC, FAHA, FASNC  
 Christopher M. Kramer, MD, FACC, FAHA  
 James K. Min, MD, FACC  
 Manesh R. Patel, MD, FACC  
 Leslee Shaw, PhD, FACC, FASNC  
 Raymond F. Stainback, MD, FACC, FASE  
 Joseph M. Allen, MA

**TABLE OF CONTENTS**

ABSTRACT .....	230
PREFACE .....	231
1. INTRODUCTION .....	232
2. METHODS .....	232
3. GENERAL ASSUMPTIONS .....	233
4. DEFINITIONS .....	233
5. RESULTS OF RATINGS .....	234
6. ECHOCARDIOGRAPHY APPROPRIATE USE CRITERIA (BY INDICATION) .....	235
Table 1: TTE for General Evaluation of Cardiac Structure and Function .....	235
Table 2: TTE for Cardiovascular Evaluation in an Acute Setting .....	235
Table 3: TTE for Evaluation of Valvular Function .....	236
Table 4: TTE for Evaluation of Intracardiac and Extracardiac Structures and Chambers .....	237
Table 5: TTE for Evaluation of Aortic Disease .....	237
Table 6: TTE for Evaluation of Hypertension, HF, or Cardiomyopathy .....	237
Table 7: TTE for Adult Congenital Heart Disease .....	238
Table 8: TEE .....	239
Table 9: Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent .....	239
Table 10: Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) .....	240
Table 11: Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities .....	240
Table 12: Stress Echocardiography Following Prior Test Results .....	241

Table 13: Stress Echocardiography for Risk Assessment: Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions .....	241
Table 14: Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS .....	242
Table 15: Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG) .....	242
Table 16: Stress Echocardiography for Assessment of Viability/Ischemia .....	242
Table 17: Stress Echocardiography for Hemodynamics (Includes Doppler During Stress) .....	243
Table 18: Contrast Use in TTE/TEE or Stress Echocardiography .....	243

7. ECHOCARDIOGRAPHY APPROPRIATE USE CRITERIA (BY APPROPRIATE USE RATING) .....	244
Table 19. Appropriate Indications (Median Score 7–9) .....	244
Table 20. Uncertain Indications (Median Score 4–6) .....	248
Table 21. Inappropriate Indications (Median Score 1–3) .....	249
8. DISCUSSION .....	253
APPENDIX A: ADDITIONAL ECHOCARDIOGRAPHY DEFINITIONS .....	259
Figure A1. Stepwise Approach to Perioperative Cardiac Assessment .....	259
Table A1: Active Cardiac Conditions for Which the Patient Should Undergo Evaluation and Treatment Before Noncardiac Surgery (Class I, Level of Evidence: B) .....	260
Table A2. Perioperative Clinical Risk Factors* .....	260
APPENDIX B: ADDITIONAL METHODS .....	260
Relationships With Industry and Other Entities .....	260
Literature Review .....	260
APPENDIX C: ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/ SCCM/SCCT/SCMR 2011 APPROPRIATE USE CRITERIA FOR ECHOCARDIOGRAPHY PARTICIPANTS .....	260
APPENDIX D: ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/ SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocar- diography Writing Group, Technical Panel, Indication Reviewers, and Task Force—Relationships With Industry and Other Entities (in Alphabetical Order Within Each Group) .....	264
REFERENCES .....	266

**ABSTRACT**

The American College of Cardiology Foundation (ACCF), in partnership with the American Society of Echocardiography (ASE) and along with key specialty and subspecialty societies, conducted a review of

### Abbreviations

<b>ACS</b>	= Acute coronary syndrome
<b>APC</b>	= Atrial premature contraction
<b>CABG</b>	= Coronary artery bypass grafting surgery
<b>CAD</b>	= Coronary artery disease
<b>CMR</b>	= Cardiovascular magnetic resonance
<b>CRT</b>	= Cardiac resynchronization therapy
<b>CT</b>	= Computed tomography
<b>ECG</b>	= Electrocardiogram
<b>HF</b>	= Heart failure
<b>ICD</b>	= Implantable cardioverter-defibrillator
<b>LBBB</b>	= Left bundle-branch block
<b>LV</b>	= Left ventricular
<b>MET</b>	= Estimated metabolic equivalents of exercise
<b>MI</b>	= Myocardial infarction
<b>PCI</b>	= Percutaneous coronary intervention
<b>RNI</b>	= Radionuclide imaging
<b>SPECT MPI</b>	= Single-photon emission computed tomography myocardial perfusion imaging
<b>STEMI</b>	= ST-segment elevation myocardial infarction
<b>SVT</b>	= Supraventricular tachycardia
<b>TEE</b>	= Transesophageal echocardiogram
<b>TIA</b>	= Transient ischemic attack
<b>TIMI</b>	= Thrombolysis In Myocardial Infarction
<b>TTE</b>	= Transthoracic echocardiogram
<b>NSTEMI/NSTEMI</b>	= Unstable angina/non-ST-segment elevation myocardial infarction
<b>VPC</b>	= Ventricular premature contraction
<b>VT</b>	= Ventricular tachycardia

common clinical scenarios where echocardiography is frequently considered. This document combines and updates the original transthoracic and transeophageal echocardiography appropriateness criteria published in 2007 (1) and the original stress echocardiography appropriateness criteria published in 2008 (2). This revision reflects new clinical data, reflects changes in test utilization patterns, and clarifies echocardiography use where omissions or lack of clarity existed in the original criteria.

The indications (clinical scenarios) were derived from common applications or anticipated uses, as well as from current clinical practice guidelines and results of studies examining the implementation of the original appropriate use criteria (AUC). The 202 indications in this document were developed by a diverse writing group and scored by a separate independent technical panel on a scale of 1 to 9, to designate appropriate use (median 7 to 9), uncertain use (median 4 to 6), and inappropriate use (median 1 to 3).

Ninety-seven indications were rated as appropriate, 34 were rated as uncertain, and 71 were rated as inappropriate. In general, the use of echocardiography for initial diagnosis when there is a change in clinical status or when the results of the echocardiogram are anticipated to change patient management were rated appropriate. Routine testing when there was no change in clinical status or when results of testing were unlikely to modify management were more likely to be inappropriate than appropriate/uncertain.

The AUC for echocardiography have the potential to impact physician decision making, healthcare delivery, and reimbursement policy. Furthermore, recognition of uncertain clinical scenarios facilitates identification of areas that would benefit from future research.

### PREFACE

In an effort to respond to the need for the rational use of imaging services in the delivery of high-quality care, the ACCF has undertaken a process to determine the appropriate use of cardiovascular imaging for selected patient indications.

AUC publications reflect an ongoing effort by the ACCF to critically and systematically create, review, and categorize clinical situations where diagnostic tests and procedures are utilized by physicians caring for patients with cardiovascular diseases. The process is based on current understanding of the technical capabilities of the imaging modalities examined. Although impossible to be entirely comprehensive given the wide diversity of clinical disease, the indications are meant to identify common scenarios encompassing the majority of situations encountered in contemporary practice. Given the breadth of information they convey, the indications do not directly correspond to the Ninth Revision of the International Classification of Diseases system as these codes do not include clinical information, such as symptom status.

The ACCF believes that careful blending of a broad range of clinical experiences and available evidence-based information will help guide a more efficient and equitable allocation of healthcare resources in cardiovascular imaging. The ultimate objective of AUC is to improve patient care and health outcomes in a cost-effective manner, but it is not intended to ignore ambiguity and nuance intrinsic to clinical decision making. AUC thus should not be considered substitutes for sound clinical judgment and practice experience.

The ACCF AUC process itself is also evolving. In the current iteration, technical panel members were asked to rate indications for echocardiography in a manner independent and irrespective of the prior published ACCF ratings for transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) (1) and stress echocardiography (2) as well as the prior ACCF ratings for diagnostic imaging modalities such as cardiac radionuclide imaging (RNI) (3) and cardiac computed tomography (CT) (4). Given the iterative and evolving nature of the process, readers are counseled that comparison of individual appropriate use ratings among modalities rated at different times over the past several years may not reflect the comparative utility of the different modalities for an indication, as the ratings may vary over time. A comparative evaluation of the appropriate use of multiple imaging techniques is currently being undertaken to assess the relative strengths of each modality for various clinical scenarios.

We are grateful to the technical panel and its chair, Steven Bailey, MD, FACC, FSCAI, FAHA, a professional group with a wide range of skills and insights, for their thoughtful and thorough deliberation of the merits of echocardiography for various indications. We would also like to thank the 27 individuals who provided a careful review of the draft of indications, the parent AUC Task Force ably led by Michael Wolk, MD, MACC, Rory Weiner, MD, and the ACC staff, John C. Lewin, MD, Joseph Allen, Starr Webb, Jenissa Haidari, and Lea Binder for their exceptionally skilled support in the generation of this document.

*Pamela S. Douglas, MD, MACC, FAHA, FASE  
Chair, Echocardiography Writing Group  
Michael J. Wolk, MD, MACC  
Chair, Appropriate Use Criteria Task Force*

## 1. INTRODUCTION

This report addresses the appropriate use of TTE, TEE, and stress echocardiography. Improvements in cardiovascular imaging technology and an expanding armamentarium of noninvasive diagnostic tools and therapeutic options for cardiovascular disease have led to an increase in cardiovascular imaging. As the field of echocardiography continues to advance along with other imaging modalities and treatment options, the healthcare community needs to understand how to best incorporate this technology into daily clinical care.

All prior AUC publications from the ACCF and collaborating organizations reflect an ongoing effort to critically and systematically create, review, and categorize the appropriate use of cardiovascular procedures and diagnostic tests. The ACCF recognizes the importance of revising these criteria in a timely manner in order to provide the cardiovascular community with the most accurate indications. Understanding the background and scope of this document are important before interpreting the rating tables.

This document presents a combination and revision of the 2007 ACCF AUC for Transthoracic and Transesophageal Echocardiography (1) and the 2008 ACCF AUC for Stress Echocardiography (2). Appropriate echocardiograms are those that are likely to contribute to improving patients' clinical outcomes, and importantly, inappropriate use of echocardiography may be potentially harmful to patients and generate unwarranted costs to the healthcare system.

## 2. METHODS

The indications included in this publication cover a wide array of cardiovascular signs and symptoms as well as clinical judgments as to the likelihood of cardiovascular findings. Within each main disease category, a standardized approach was used to capture the majority of clinical scenarios without making the list of indications excessive. The approach was to create 5 broad clinical scenarios regarding the possible use of echocardiography: 1) for initial diagnosis; 2) to guide therapy or management, regardless of symptom status; 3) to evaluate a change in clinical status or cardiac exam; 4) for early follow-up without change in clinical status; and 5) for late follow-up without change in clinical status. Certain specific clinical scenarios were addressed with additional focused indications.

The indications were constructed by experts in echocardiography and in other fields and were modified on the basis of discussions among the task force and feedback from independent reviewers and the technical panel. Wherever possible, indications were mapped to relevant clinical guidelines and key publications/references (Online Appendix).

An important focus during the indication revision process was to harmonize the indications across noninvasive modalities, such that the wording of the indications are similar with other AUC (3) whenever it was feasible to do so. New indications as well as indication tables were created, although it remains likely that several clinical scenarios are not covered by these revised AUC for echocardiography. Once the revised indications were written, they were reviewed and critiqued by the parent AUC Task Force and by 27 external re-

viewers representing all cardiovascular specialties and primary care before being finalized.

A detailed description of the methods used for ranking the selected clinical indications is found in a previous publication, "ACCF Proposed Method for Evaluating the Appropriateness of Cardiovascular Imaging" (5). Briefly, this process combines evidence-based medicine and practice experience by engaging a technical panel in a modified Delphi exercise. Since the original TTE/TEE (1) and stress echocardiography (2) documents and methods paper (5) were published, several important processes have been put in place to further enhance the rigor of this process. They include convening a formal writing group with diverse expertise in imaging and clinical care, circulating the indications for external review prior to rating by the technical panel, ensuring appropriate balance of expertise and practice area of the technical panel, development of a standardized rating package, and establishment of formal roles for facilitating panel interaction at the face-to-face meeting.

The technical panel first rated indications independently. Then, the panel was convened for a face-to-face meeting for discussion of each indication. At this meeting, panel members were provided with their scores and a blinded summary of their peers' scores. After the meeting, panel members were then asked to independently provide their final scores for each indication.

Although panel members were not provided explicit cost information to help determine their appropriate use ratings, they were asked to implicitly consider cost as an additional factor in their evaluation of appropriate use. In rating these criteria, the technical panel was asked to assess whether the use of the test for each indication is appropriate, uncertain, or inappropriate, and was provided the following definition of appropriate use:

***An appropriate imaging study is one in which the expected incremental information, combined with clinical judgment, exceeds the expected negative consequence\* by a sufficiently wide margin for a specific indication that the procedure is generally considered acceptable care and a reasonable approach for the indication.***

The technical panel scored each indication as follows:

Median Score 7 to 9

Appropriate test for specific indication (test **is** generally acceptable and **is** a reasonable approach for the indication).

Median Score 4 to 6

Uncertain for specific indication (test **may** be generally acceptable and **may** be a reasonable approach for the indication). Uncertainty also implies that more research and/or patient information is needed to classify the indication definitively.

Median Score 1 to 3

Inappropriate test for that indication (test **is not** generally acceptable and **is not** a reasonable approach for the indication).

The division of these scores into 3 levels of appropriateness is somewhat arbitrary, and the numeric designations should be viewed as a continuum. Further, there is diversity in clinical opinion for particular clinical scenarios, such that scores in the intermediate level of appropriate use should be labeled "uncertain," as critical patient or research data may be lacking or discordant. This designation should be a prompt to the field to carry out definitive

\*Negative consequences include the risks of the procedure (i.e., radiation or contrast exposure) and the downstream impact of poor test performance such as delay in diagnosis (false-negatives) or inappropriate diagnosis (false-positives).

research investigations whenever possible. It is anticipated that the AUC reports will continue to be revised as further data are generated and information from the implementation of the criteria is accumulated.

To prevent bias in the scoring process, the technical panel was deliberately comprised of a minority of specialists in echocardiography. Specialists, although offering important clinical and technical insights, might have a natural tendency to rate the indications within their specialty as more appropriate than nonspecialists. In addition, care was taken in providing objective, nonbiased information, including guidelines and key references, to the technical panel.

The level of agreement among panelists as defined by RAND (6) was analyzed based on the BIOMED rule for a panel of 14 to 16 members. As such, agreement was defined as an indication where 4 or fewer panelists' ratings fell outside the 3-point region containing the median score.

Disagreement was defined as where at least 5 panelists' ratings fell in both the appropriate and the inappropriate categories. Any indication having disagreement was categorized as uncertain regardless of the final median score. Indications that met neither definition for agreement or disagreement are in a third, unlabeled category.

### 3. GENERAL ASSUMPTIONS

---

To prevent any inconsistencies in interpretation, specific assumptions were considered by the writing group in developing the indications and by the technical panel when rating the clinical indications for the appropriate use of inpatient and outpatient adult TTE/TEE and stress echocardiography.

1. ATTE and a TEE examination and report will include the use and interpretation of 2-dimensional/M-mode imaging, color flow Doppler, and spectral Doppler as important elements of a comprehensive TTE/TEE (7–9) evaluating relevant cardiac structures and hemodynamics. Stress echocardiography will include rest and stress 2-dimensional imaging at a minimum unless performed for hemodynamics, when Doppler must be included (10).
2. All standard echocardiographic techniques for image acquisition, including standard rest imaging and stress protocols (10), are available for each indication and have a sensitivity and specificity similar to those found in the published literature. Selection for and monitoring of contrast use is assumed to be in accord with practice guidelines (11).
3. The test is performed and interpreted by qualified individual(s) in a facility that is proficient in the echocardiographic technique (12,13).
4. The range of potential indications for echocardiography is quite large, particularly in comparison with other cardiovascular imaging tests. Thus, the indications are, at times, purposefully broad to cover an array of cardiovascular signs and symptoms as well as the ordering physician's best judgment as to the presence of cardiovascular abnormalities. Additionally, there are likely clinical scenarios that are not covered in this document.
5. A complete clinical history and physical exam has been completed by a qualified clinician such that the clinical status of the patient can be assumed to be valid as stated in the indication (e.g., an asymptomatic patient is truly asymptomatic for the condition in question and that sufficient questioning of the patient has been undertaken).
6. If the reason for a test can be assigned to more than 1 indication, it should be classified under the most appropriate indication.
7. Cost should be considered implicitly in the appropriate use determination.
8. For each indication, the rating should reflect whether the echocardiogram is reasonable for the patient according to the appropriate use definition, not

whether the test is preferred over another modality. It should not be assumed that for each indication the decision to perform a diagnostic test has already been made. It also should not consider issues of local availability or skill for any modality or attempt in any way to compare 2 tests with each other.

9. The category of "uncertain" should be used when insufficient clinical data are available for a definitive categorization or there is substantial disagreement regarding the appropriateness of that indication. The designation of "uncertain" should not be used as grounds for denial of reimbursement.
10. Indications that describe routine or surveillance echocardiograms imply that the test is being considered for a "periodic" evaluation since a certain period of time has elapsed. The test is not being ordered due to the anticipation of changing clinical decision making or guiding therapy.
11. Prosthetic valves and native valves are to be considered together, except where specifically mentioned otherwise in this document. The severity of valve stenosis or regurgitation is defined in clinical guidelines (14,15).
12. In general, it is assumed that TEE is most appropriately used as an adjunct or subsequent test to TTE when indicated, such as when suboptimal TTE images preclude obtaining a diagnostic study. The indications for which TEE may reasonably be the test of first choice include, but are not limited to, the indications presented in Table 8 of this document.
13. Intraoperative TEE is an important use of cardiovascular ultrasound. However, this application is outside the scope of this document and thus is not addressed here.
14. For all stress imaging, the mode of stress testing is assumed to be exercise (e.g., treadmill, bicycle) for patients able to exercise. For patients unable to exercise, it is assumed that dobutamine is used for echocardiographic stress testing. Any indications requiring a specific mode of stress (e.g., when hemodynamic information is required) are labeled as such.
15. Doppler hemodynamic assessment during stress echocardiography includes both right and left heart hemodynamics (e.g., valvular gradients, pulmonary artery pressure, mitral regurgitation severity).
16. The indications for the perioperative evaluation for noncardiac surgery were modeled after the ACCF/AHA guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery (16). If a patient has signs/symptoms of suspected cardiac etiology, the clinical scenario should be considered in the symptomatic category (e.g., Indication 1) and not in the perioperative section.
17. As with other surgeries, the need for coronary artery disease (CAD) assessment prior to solid organ transplantation is related to patient and surgical risk. In general, solid organ transplantation should be considered in the vascular surgery category given that CAD is common in patients with diabetes mellitus who have end-stage renal disease.

### 4. DEFINITIONS

---

Definitions of terms used throughout the indication set are listed here. Additional definitions are listed in Appendix A. These definitions were provided to and discussed with the technical panel prior to ratings of indications.

1. **Ischemic Equivalent: Chest Pain Syndrome, Anginal Equivalent, or Ischemic Electrocardiographic Abnormalities:** Any constellation of clinical findings that the physician feels is consistent with CAD. Examples of such findings include, but are not limited to, chest pain, chest tightness, chest burning, shoulder pain, palpitations, jaw pain, new electrocardiographic abnormalities, or other symptoms/findings suggestive of CAD. Nonchest pain symptoms (e.g., dyspnea or reduced/worsening effort tolerance) that are thought to be consistent with CAD may also be considered to be an ischemic equivalent.
2. **Global CAD Risk:** It is assumed that clinicians will use current standard methods of global risk assessment such as those presented in the National

**Table A** Pretest probability of CAD by age, gender, and symptoms\*

Age (years)	Gender	Typical/Definite angina pectoris	Atypical/Probable angina pectoris	Nonanginal chest pain	Asymptomatic
<39	Men	Intermediate	Intermediate	Low	Very low
	Women	Intermediate	Very low	Very low	Very low
40–49	Men	High	Intermediate	Intermediate	Low
	Women	Intermediate	Low	Very low	Very low
50–59	Men	High	Intermediate	Intermediate	Low
	Women	Intermediate	Intermediate	Low	Very low
>60	Men	High	Intermediate	Intermediate	Low
	Women	High	Intermediate	Intermediate	Low

**High:** >90% pretest probability; **Intermediate:** Between 10% and 90% pretest probability; **Low:** Between 5% and 10% pretest probability; **Very low:** <5% pretest probability.

\*Modified from the ACC/AHA Exercise Testing Guidelines to reflect all age ranges.

Heart, Lung, and Blood Institute report on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III IATP III) (18) or similar national guidelines.

Absolute risk is defined as the probability of developing CAD over a given time period. The ATP III report specifies absolute risk for CAD over the next 10 years. CAD risk refers to 10-year risk for any hard cardiac event (e.g., myocardial infarction or CAD death). However, acknowledging that global absolute risk scores may be miscalibrated in certain populations (e.g., women, younger men), clinical judgment must be applied in assigning categorical risk thresholds in such sub-populations.

#### • Low global CAD risk

Defined by the age-specific risk level that is below average. In general, low risk will correlate with a 10-year absolute CAD risk <10%. However, in women and younger men, low risk may correlate with 10-year absolute CAD risk <6%.

#### • Intermediate global CAD risk

Defined by the age-specific risk level that is average. In general, moderate risk will correlate with a 10-year absolute CAD risk range of 10% to 20%. Among women and younger age men, an expanded intermediate risk range of 6% to 20% may be appropriate.

#### • High global CAD risk

Defined by the age-specific risk level that is above average. In general, high risk will correlate with a 10-year absolute CAD risk of >20%. CAD equivalents (e.g., diabetes mellitus, peripheral arterial disease) can also define high risk.

### 3. Pretest Probability of CAD: Symptomatic (Ischemic Equivalent)

**Patients:** Once the physician determines that symptoms are present that may represent CAD, the pretest probability of CAD should be assessed. There are a number of risk algorithms (19,20) available that can be used to calculate this probability. Clinicians should be familiar with those algorithms that pertain to the populations they encounter most often. In scoring the indications, the following probabilities, as calculated from any of the various available validated algorithms, should be applied.

- **Very low pretest probability:** <5% pretest probability of CAD
- **Low pretest probability:** Between 5% and 10% pretest probability of CAD
- **Intermediate pretest probability:** Between 10% and 90% pretest probability of CAD
- **High pretest probability:** >90% pretest probability of CAD

The method recommended by the ACC/AHA guidelines for chronic stable angina (21) is provided as one example of a method used to calculate pretest probability and is a modification of a previously published literature review (22). Please refer to Table A and the definition of angina in Appendix A. It is important to note that other historical factors or electrocardiographic findings (e.g., prior infarction) can affect pretest probability, although these factors are not accounted for in Table A. Similarly, although not incorporated into the algorithm, other CAD risk factors may also affect pretest likelihood of CAD. Detailed nomograms are available that incorporate the effects of a history of prior infarction, electrocardiographic Q waves and ST- and T-wave changes, diabetes, smoking, and hypercholesterolemia(23).

## 5. RESULTS OF RATINGS

The final ratings for echocardiography are listed by indication in Tables 1 to 18. The final score reflects the median score of the 15 technical panel members and has been labeled according to the 3 appropriate use categories of appropriate (median 7 to 9), uncertain (median 4 to 6), and inappropriate (median 1 to 3). Tables 19 to 21 present the indications by the appropriate use categories.

There was less variation in ratings for the indications labeled as either appropriate or inappropriate, with 92% and 90%, respectively, showing agreement as defined in Methods Section 2. There was greater variability (less agreement) in the rating scores for indications defined as uncertain, with 21% showing agreement as defined previously. Two indications, 182 and 189, were distributed into each extreme such that the panel was classified as being in disagreement. However, the median scores for these indications were already placed in the uncertain category, so no changes were required to reflect disagreement. Across all categories, 40 indications did not meet the definition of agreement; however, the scores were not so divergent (as defined by disagreement) as to necessitate a change in the final score.

Visual representations (flow diagrams) for all indications are included in the Online Appendix.

Selected flow diagrams for several categories of indications are included here (Figs. 1 to 6).

## 6. ECHOCARDIOGRAPHY APPROPRIATE USE CRITERIA (BY INDICATION)

**Table 1** TTE for general evaluation of cardiac structure and function

Indication	Appropriate use score (1–9)
<b>Suspected Cardiac Etiology—General With TTE</b>	
1. • Symptoms or conditions potentially related to suspected cardiac etiology including but not limited to chest pain, shortness of breath, palpitations, TIA, stroke, or peripheral embolic event	A (9)
2. • Prior testing that is concerning for heart disease or structural abnormality including but not limited to chest X-ray, baseline scout images for stress echocardiogram, ECG, or cardiac biomarkers	A (9)
<b>Arrhythmias With TTE</b>	
3. • Infrequent APCs or infrequent VPCs without other evidence of heart disease	I (2)
4. • Frequent VPCs or exercise-induced VPCs	A (8)
5. • Sustained or nonsustained atrial fibrillation, SVT, or VT	A (9)
6. • Asymptomatic isolated sinus bradycardia	I (2)
<b>Lightheadedness/Presyncope/Syncope With TTE</b>	
7. • Clinical symptoms or signs consistent with a cardiac diagnosis known to cause lightheadedness/presyncope/syncope (including but not limited to aortic stenosis, hypertrophic cardiomyopathy, or HF)	A (9)
8. • Lightheadedness/presyncope when there are no other symptoms or signs of cardiovascular disease	I (3)
9. • Syncope when there are no other symptoms or signs of cardiovascular disease	A (7)
<b>Evaluation of Ventricular Function With TTE</b>	
10. • Initial evaluation of ventricular function (e.g., screening) with no symptoms or signs of cardiovascular disease	I (2)
11. • Routine surveillance of ventricular function with known CAD and no change in clinical status or cardiac exam	I (3)
12. • Evaluation of LV function with prior ventricular function evaluation showing normal function (e.g., prior echocardiogram, left ventriculogram, CT, SPECT MPI, CMR) in patients in whom there has been no change in clinical status or cardiac exam	I (1)
<b>Perioperative Evaluation With TTE</b>	
13. • Routine perioperative evaluation of ventricular function with no symptoms or signs of cardiovascular disease	I (2)
14. • Routine perioperative evaluation of cardiac structure and function prior to noncardiac solid organ transplantation	U (6)
<b>Pulmonary Hypertension With TTE</b>	
15. • Evaluation of suspected pulmonary hypertension including evaluation of right ventricular function and estimated pulmonary artery pressure	A (9)
16. • Routine surveillance (<1 y) of known pulmonary hypertension without change in clinical status or cardiac exam	I (3)
17. • Routine surveillance (≥1 y) of known pulmonary hypertension without change in clinical status or cardiac exam	A (7)
18. • Re-evaluation of known pulmonary hypertension if change in clinical status or cardiac exam or to guide therapy	A (9)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 2** TTE for cardiovascular evaluation in an acute setting

Indication	Appropriate use score (1–9)
<b>Hypotension or Hemodynamic Instability With TTE</b>	
19. • Hypotension or hemodynamic instability of uncertain or suspected cardiac etiology	A (9)
20. • Assessment of volume status in a critically ill patient	U (5)
<b>Myocardial Ischemia/Infarction With TTE</b>	
21. • Acute chest pain with suspected MI and nondiagnostic ECG when a resting echocardiogram can be performed during pain	A (9)
22. • Evaluation of a patient without chest pain but with other features of an ischemic equivalent or laboratory markers indicative of ongoing MI	A (8)
23. • Suspected complication of myocardial ischemia/infarction, including but not limited to acute mitral regurgitation, ventricular septal defect, free-wall rupture/tamponade, shock, right ventricular involvement, HF, or thrombus	A (9)
<b>Evaluation of Ventricular Function after ACS With TTE</b>	
24. • Initial evaluation of ventricular function following ACS	A (9)
25. • Re-evaluation of ventricular function following ACS during recovery phase when results will guide therapy	A (9)
<b>Respiratory Failure With TTE</b>	
26. • Respiratory failure or hypoxemia of uncertain etiology	A (8)
27. • Respiratory failure or hypoxemia when a noncardiac etiology of respiratory failure has been established	U (5)

(Continued)

**Table 2** (Continued)

Indication	Appropriate use score (1–9)
<b>Pulmonary Embolism With TTE</b>	
28. • Suspected pulmonary embolism in order to establish diagnosis	I (2)
29. • Known acute pulmonary embolism to guide therapy (e.g., thrombectomy and thrombolytics)	A (8)
30. • Routine surveillance of prior pulmonary embolism with normal right ventricular function and pulmonary artery systolic pressure	I (1)
31. • Re-evaluation of known pulmonary embolism after thrombolysis or thrombectomy for assessment of change in right ventricular function and/or pulmonary artery pressure	A (7)
<b>Cardiac Trauma With TTE</b>	
32. • Severe deceleration injury or chest trauma when valve injury, pericardial effusion, or cardiac injury are possible or suspected	A (9)
33. • Routine evaluation in the setting of mild chest trauma with no electrocardiographic changes or biomarker elevation	I (2)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 3** TTE for evaluation of valvular function

Indication	Appropriate use score (1–9)
<b>Murmur or Click With TTE</b>	
34. • Initial evaluation when there is a reasonable suspicion of valvular or structural heart disease	A (9)
35. • Initial evaluation when there are no other symptoms or signs of valvular or structural heart disease	I (2)
36. • Re-evaluation in a patient without valvular disease on prior echocardiogram and no change in clinical status or cardiac exam	I (1)
37. • Re-evaluation of known valvular heart disease with a change in clinical status or cardiac exam or to guide therapy	A (9)
<b>Native Valvular Stenosis With TTE</b>	
38. • Routine surveillance (<3 y) of mild valvular stenosis without a change in clinical status or cardiac exam	I (3)
39. • Routine surveillance ( $\geq 3$ y) of mild valvular stenosis without a change in clinical status or cardiac exam	A (7)
40. • Routine surveillance (<1 y) of moderate or severe valvular stenosis without a change in clinical status or cardiac exam	I (3)
41. • Routine surveillance ( $\geq 1$ y) of moderate or severe valvular stenosis without a change in clinical status or cardiac exam	A (8)
<b>Native Valvular Regurgitation With TTE</b>	
42. • Routine surveillance of trace valvular regurgitation	I (1)
43. • Routine surveillance (<3 y) of mild valvular regurgitation without a change in clinical status or cardiac exam	I (2)
44. • Routine surveillance ( $\geq 3$ y) of mild valvular regurgitation without a change in clinical status or cardiac exam	U (4)
45. • Routine surveillance (<1 y) of moderate or severe valvular regurgitation without a change in clinical status or cardiac exam	U (6)
46. • Routine surveillance ( $\geq 1$ y) of moderate or severe valvular regurgitation without change in clinical status or cardiac exam	A (8)
<b>Prosthetic Valves With TTE</b>	
47. • Initial postoperative evaluation of prosthetic valve for establishment of baseline	A (9)
48. • Routine surveillance (<3 y after valve implantation) of prosthetic valve if no known or suspected valve dysfunction	I (3)
49. • Routine surveillance ( $\geq 3$ y after valve implantation) of prosthetic valve if no known or suspected valve dysfunction	A (7)
50. • Evaluation of prosthetic valve with suspected dysfunction or a change in clinical status or cardiac exam	A (9)
51. • Re-evaluation of known prosthetic valve dysfunction when it would change management or guide therapy	A (9)
<b>Infective Endocarditis (Native or Prosthetic Valves) With TTE</b>	
52. • Initial evaluation of suspected infective endocarditis with positive blood cultures or a new murmur	A (9)
53. • Transient fever without evidence of bacteremia or a new murmur	I (2)

(Continued)

**Table 3** (Continued)

Indication	Appropriate use score (1–9)
54. • Transient bacteremia with a pathogen not typically associated with infective endocarditis and/or a documented nonendovascular source of infection	I (3)
55. • Re-evaluation of infective endocarditis at high risk for progression or complication or with a change in clinical status or cardiac exam	A (9)
56. • Routine surveillance of uncomplicated infective endocarditis when no change in management is contemplated	I (2)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 4** TTE for evaluation of intracardiac and extracardiac structures and chambers

Indication	Appropriate use score (1–9)
57. • Suspected cardiac mass	A (9)
58. • Suspected cardiovascular source of embolus	A (9)
59. • Suspected pericardial conditions	A (9)
60. • Routine surveillance of known small pericardial effusion with no change in clinical status	I (2)
61. • Re-evaluation of known pericardial effusion to guide management or therapy	A (8)
62. • Guidance of percutaneous noncoronary cardiac procedures including but not limited to pericardiocentesis, septal ablation, or right ventricular biopsy	A (9)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 5** TTE for evaluation of aortic disease

Indication	Appropriate use score (1–9)
63. • Evaluation of the ascending aorta in the setting of a known or suspected connective tissue disease or genetic condition that predisposes to aortic aneurysm or dissection (e.g., Marfan syndrome)	A (9)
64. • Re-evaluation of known ascending aortic dilation or history of aortic dissection to establish a baseline rate of expansion or when the rate of expansion is excessive	A (9)
65. • Re-evaluation of known ascending aortic dilation or history of aortic dissection with a change in clinical status or cardiac exam or when findings may alter management or therapy	A (9)
66. • Routine re-evaluation for surveillance of known ascending aortic dilation or history of aortic dissection without a change in clinical status or cardiac exam when findings would not change management or therapy	I (3)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 6** TTE for evaluation of hypertension, HF, or cardiomyopathy

Indication	Appropriate Use score (1–9)
<b>Hypertension With TTE</b>	
67. • Initial evaluation of suspected hypertensive heart disease	A (8)
68. • Routine evaluation of systemic hypertension without symptoms or signs of hypertensive heart disease	I (3)
69. • Re-evaluation of known hypertensive heart disease without a change in clinical status or cardiac exam	U (4)
<b>HF With TTE</b>	
70. • Initial evaluation of known or suspected HF (systolic or diastolic) based on symptoms, signs, or abnormal test results	A (9)
71. • Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac exam without a clear precipitating change in medication or diet	A (8)
72. • Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac exam with a clear precipitating change in medication or diet	U (4)
73. • Re-evaluation of known HF (systolic or diastolic) to guide therapy	A (9)

(Continued)

**Table 6** (Continued)

Indication	Appropriate Use score (1–9)
74. • Routine surveillance (<1 y) of HF (systolic or diastolic) when there is no change in clinical status or cardiac exam	I (2)
75. • Routine surveillance ( $\geq 1$ y) of HF (systolic or diastolic) when there is no change in clinical status or cardiac exam	U (6)
<b>Device Evaluation (Including Pacemaker, ICD, or CRT) With TTE</b>	
76. • Initial evaluation or re-evaluation after revascularization and/or optimal medical therapy to determine candidacy for device therapy and/or to determine optimal choice of device	A (9)
77. • Initial evaluation for CRT device optimization after implantation	U (6)
78. • Known implanted pacing device with symptoms possibly due to device complication or suboptimal pacing device settings	A (8)
79. • Routine surveillance (<1 y) of implanted device without a change in clinical status or cardiac exam	I (1)
80. • Routine surveillance ( $\geq 1$ y) of implanted device without a change in clinical status or cardiac exam	I (3)
<b>Ventricular Assist Devices and Cardiac Transplantation With TTE</b>	
81. • To determine candidacy for ventricular assist device	A (9)
82. • Optimization of ventricular assist device settings	A (7)
83. • Re-evaluation for signs/symptoms suggestive of ventricular assist device-related complications	A (9)
84. • Monitoring for rejection in a cardiac transplant recipient	A (7)
85. • Cardiac structure and function evaluation in a potential heart donor	A (9)
<b>Cardiomyopathies With TTE</b>	
86. • Initial evaluation of known or suspected cardiomyopathy (e.g., restrictive, infiltrative, dilated, hypertrophic, or genetic cardiomyopathy)	A (9)
87. • Re-evaluation of known cardiomyopathy with a change in clinical status or cardiac exam or to guide therapy	A (9)
88. • Routine surveillance (<1 y) of known cardiomyopathy without a change in clinical status or cardiac exam	I (2)
89. • Routine surveillance ( $\geq 1$ y) of known cardiomyopathy without a change in clinical status or cardiac exam	U (5)
90. • Screening evaluation for structure and function in first-degree relatives of a patient with an inherited cardiomyopathy	A (9)
91. • Baseline and serial re-evaluations in a patient undergoing therapy with cardiotoxic agents	A (9)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 7** TTE for adult congenital heart disease

Indication	Appropriate use score (1–9)
92. • Initial evaluation of known or suspected adult congenital heart disease	A (9)
93. • Known adult congenital heart disease with a change in clinical status or cardiac exam	A (9)
94. • Re-evaluation to guide therapy in known adult congenital heart disease	A (9)
95. • Routine surveillance (<2 y) of adult congenital heart disease following complete repair <ul style="list-style-type: none"> <li>◦ without a residual structural or hemodynamic abnormality</li> <li>◦ without a change in clinical status or cardiac exam</li> </ul>	I (3)
96. • Routine surveillance ( $\geq 2$ y) of adult congenital heart disease following complete repair <ul style="list-style-type: none"> <li>◦ without residual structural or hemodynamic abnormality</li> <li>◦ without a change in clinical status or cardiac exam</li> </ul>	U (6)
97. • Routine surveillance (<1 y) of adult congenital heart disease following incomplete or palliative repair <ul style="list-style-type: none"> <li>◦ with residual structural or hemodynamic abnormality</li> <li>◦ without a change in clinical status or cardiac exam</li> </ul>	U (5)
98. • Routine surveillance ( $\geq 1$ y) of adult congenital heart disease following incomplete or palliative repair <ul style="list-style-type: none"> <li>◦ with residual structural or hemodynamic abnormality</li> <li>◦ without a change in clinical status or cardiac exam</li> </ul>	A (8)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 8** TEE

Indication	Appropriate use score (1–9)
<b>TEE as Initial or Supplemental Test—General Uses</b>	
99. ● Use of TEE when there is a high likelihood of a nondiagnostic TTE due to patient characteristics or inadequate visualization of relevant structures	A (8)
100. ● Routine use of TEE when a diagnostic TTE is reasonably anticipated to resolve all diagnostic and management concerns	I (1)
101. ● Re-evaluation of prior TEE finding for interval change (e.g., resolution of thrombus after anticoagulation, resolution of vegetation after antibiotic therapy) when a change in therapy is anticipated	A (8)
102. ● Surveillance of prior TEE finding for interval change (e.g., resolution of thrombus after anticoagulation, resolution of vegetation after antibiotic therapy) when no change in therapy is anticipated	I (2)
103. ● Guidance during percutaneous noncoronary cardiac interventions including but not limited to closure device placement, radiofrequency ablation, and percutaneous valve procedures	A (9)
104. ● Suspected acute aortic pathology including but not limited to dissection/transsection	A (9)
105. ● Routine assessment of pulmonary veins in an asymptomatic patient status post pulmonary vein isolation	I (3)
<b>TEE as Initial or Supplemental Test—Valvular Disease</b>	
106. ● Evaluation of valvular structure and function to assess suitability for, and assist in planning of, an intervention	A (9)
107. ● To diagnose infective endocarditis with a low pretest probability (e.g., transient fever, known alternative source of infection, or negative blood cultures/atypical pathogen for endocarditis)	I (3)
108. ● To diagnose infective endocarditis with a moderate or high pretest probability (e.g., staph bacteremia, fungemia, prosthetic heart valve, or intracardiac device)	A (9)
<b>TEE as Initial or Supplemental Test—Embolitic Event</b>	
109. ● Evaluation for cardiovascular source of embolus with no identified noncardiac source	A (7)
110. ● Evaluation for cardiovascular source of embolus with a previously identified noncardiac source	U (5)
111. ● Evaluation for cardiovascular source of embolus with a known cardiac source in which a TEE would not change management	I (1)
<b>TEE as Initial Test—Atrial Fibrillation/Flutter</b>	
112. ● Evaluation to facilitate clinical decision making with regard to anticoagulation, cardioversion, and/or radiofrequency ablation	A (9)
113. ● Evaluation when a decision has been made to anticoagulate and not to perform cardioversion	I (2)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 9** Stress echocardiography for detection of CAD/Risk assessment: Symptomatic or ischemic equivalent

Indication	Appropriate use score (1–9)
<b>Evaluation of Ischemic Equivalent (Nonacute) With Stress Echocardiography</b>	
114. ● Low pretest probability of CAD ● ECG interpretable and able to exercise	I (3)
115. ● Low pretest probability of CAD ● ECG uninterpretable or unable to exercise	A (7)
116. ● Intermediate pretest probability of CAD ● ECG interpretable and able to exercise	A (7)
117. ● Intermediate pretest probability of CAD ● ECG uninterpretable or unable to exercise	A (9)
118. ● High pretest probability of CAD ● Regardless of ECG interpretability and ability to exercise	A (7)
<b>Acute Chest Pain With Stress Echocardiography</b>	
119. ● Possible ACS ● ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm ● Low-risk TIMI score ● Negative troponin levels	A (7)

(Continued)

**Table 9** (Continued)

Indication	Appropriate use score (1–9)
120. <ul style="list-style-type: none"> <li>• Possible ACS</li> <li>• ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm</li> <li>• Low-risk TIMI score</li> <li>• Peak troponin: borderline, equivocal, minimally elevated</li> </ul>	A (7)
121. <ul style="list-style-type: none"> <li>• Possible ACS</li> <li>• ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm</li> <li>• High-risk TIMI score</li> <li>• Negative troponin levels</li> </ul>	A (7)
122. <ul style="list-style-type: none"> <li>• Possible ACS</li> <li>• ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm</li> <li>• High-risk TIMI score</li> <li>• Peak troponin: borderline, equivocal, minimally elevated</li> </ul>	A (7)
123. <ul style="list-style-type: none"> <li>• Definite ACS</li> </ul>	I (1)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 10** Stress echocardiography for detection of CAD/Risk assessment: Asymptomatic (without ischemic equivalent)

Indication	Appropriate use score (1–9)
<b>General Patient Populations With Stress Echocardiography</b>	
124. <ul style="list-style-type: none"> <li>• Low global CAD risk</li> </ul>	I (1)
125. <ul style="list-style-type: none"> <li>• Intermediate global CAD risk</li> <li>• ECG interpretable</li> </ul>	I (2)
126. <ul style="list-style-type: none"> <li>• Intermediate global CAD risk</li> <li>• ECG uninterpretable</li> </ul>	U (5)
127. <ul style="list-style-type: none"> <li>• High global CAD risk</li> </ul>	U (5)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 11** Stress echocardiography for detection of CAD/Risk assessment: Asymptomatic (without ischemic equivalent) in patient populations with defined comorbidities

Indication	Appropriate use score (1–9)
<b>New-Onset or Newly Diagnosed HF or LV Systolic Dysfunction With Stress Echocardiography</b>	
128. <ul style="list-style-type: none"> <li>• No prior CAD evaluation and no planned coronary angiography</li> </ul>	A (7)
<b>Arrhythmias With Stress Echocardiography</b>	
129. <ul style="list-style-type: none"> <li>• Sustained VT</li> </ul>	A (7)
130. <ul style="list-style-type: none"> <li>• Frequent PVCs, exercise induced VT, or nonsustained VT</li> </ul>	A (7)
131. <ul style="list-style-type: none"> <li>• Infrequent PVCs</li> </ul>	I (3)
132. <ul style="list-style-type: none"> <li>• New-onset atrial fibrillation</li> </ul>	U (6)
<b>Syncope With Stress Echocardiography</b>	
133. <ul style="list-style-type: none"> <li>• Low global CAD risk</li> </ul>	I (3)
134. <ul style="list-style-type: none"> <li>• Intermediate or high global CAD risk</li> </ul>	A (7)
<b>Elevated Troponin With Stress Echocardiography</b>	
135. <ul style="list-style-type: none"> <li>• Troponin elevation without symptoms or additional evidence of ACS</li> </ul>	A (7)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 12** Stress echocardiography following prior test results

Indication	Appropriate use score (1–9)
<b>Asymptomatic: Prior Evidence of Subclinical Disease With Stress Echocardiography</b>	
136. • Coronary calcium Agatston score <100	I (2)
137. • Low to intermediate global CAD risk • Coronary calcium Agatston score between 100 and 400	U (5)
138. • High global CAD risk • Coronary calcium Agatston score between 100 and 400	U (6)
139. • Coronary calcium Agatston score >400	A (7)
140. • Abnormal carotid intimal medial thickness ( $\geq 0.9$ mm and/or the presence of plaque encroaching into the arterial lumen)	U (5)
<b>Coronary Angiography (Invasive or Noninvasive) With Stress Echocardiography</b>	
141. • Coronary artery stenosis of unclear significance	A (8)
<b>Asymptomatic or Stable Symptoms With Stress Echocardiography Normal Prior Stress Imaging Study</b>	
142. • Low global CAD risk • Last stress imaging study <2 y ago	I (1)
143. • Low global CAD risk • Last stress imaging study $\geq 2$ y ago	I (2)
144. • Intermediate to high global CAD risk • Last stress imaging study <2 y ago	I (2)
145. • Intermediate to high global CAD risk • Last stress imaging study $\geq 2$ y ago	U (4)
<b>Asymptomatic or Stable Symptoms With Stress Echocardiography Abnormal Coronary Angiography or Abnormal Prior Stress Study No Prior Revascularization</b>	
146. • Known CAD on coronary angiography or prior abnormal stress imaging study • Last stress imaging study <2 y ago	I (3)
147. • Known CAD on coronary angiography or prior abnormal stress imaging study • Last stress imaging study $\geq 2$ y ago	U (5)
<b>Treadmill ECG Stress Test With Stress Echocardiography</b>	
148. • Low-risk treadmill score (e.g., Duke)	I (1)
149. • Intermediate-risk treadmill score (e.g., Duke)	A (7)
150. • High-risk treadmill score (e.g., Duke)	A (7)
<b>New or Worsening Symptoms With Stress Echocardiography</b>	
151. • Abnormal coronary angiography or abnormal prior stress imaging study	A (7)
152. • Normal coronary angiography or normal prior stress imaging study	U (6)
<b>Prior Noninvasive Evaluation With Stress Echocardiography</b>	
153. • Equivocal, borderline, or discordant stress testing where obstructive CAD remains a concern	A (8)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 13** Stress echocardiography for risk assessment: Perioperative evaluation for noncardiac surgery without active cardiac conditions

Indication	Appropriate use score (1–9)
<b>Low-Risk Surgery With Stress Echocardiography</b>	
154. • Perioperative evaluation for risk assessment	I (1)
<b>Intermediate-Risk Surgery With Stress Echocardiography</b>	
155. • Moderate to good functional capacity ( $\geq 4$ METs)	I (3)
156. • No clinical risk factors	I (2)
157. • $\geq 1$ clinical risk factor • Poor or unknown functional capacity (<4 METs)	U (6)
158. • Asymptomatic <1 y post normal catheterization, noninvasive test, or previous revascularization	I (1)
<b>Vascular Surgery With Stress Echocardiography</b>	
159. • Moderate to good functional capacity ( $\geq 4$ METs)	I (3)
160. • No clinical risk factors	I (2)
161. • $\geq 1$ clinical risk factor • Poor or unknown functional capacity (<4 METs)	A (7)
162. • Asymptomatic <1 y post normal catheterization, noninvasive test, or previous revascularization	I (2)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 14** Stress echocardiography for risk assessment: Within 3 months of an ACS

Indication	Appropriate use score (1–9)
<b>STEMI With Stress Echocardiography</b>	
163. <ul style="list-style-type: none"> <li>• Primary PCI with complete revascularization</li> <li>• No recurrent symptoms</li> </ul>	I (2)
164. <ul style="list-style-type: none"> <li>• Hemodynamically stable, no recurrent chest pain symptoms, or no signs of HF</li> <li>• To evaluate for inducible ischemia</li> <li>• No prior coronary angiography since the index event</li> </ul>	A (7)
165. <ul style="list-style-type: none"> <li>• Hemodynamically unstable, signs of cardiogenic shock, or mechanical complications</li> </ul>	I (1)
<b>UA/NSTEMI With Stress Echocardiography</b>	
166. <ul style="list-style-type: none"> <li>• Hemodynamically stable, no recurrent chest pain symptoms, or no signs of HF</li> <li>• To evaluate for inducible ischemia</li> <li>• No prior coronary angiography since the index event</li> </ul>	A (8)
<b>ACS—Asymptomatic Postrevascularization (PCI or CABG) With Stress Echocardiography</b>	
167. <ul style="list-style-type: none"> <li>• Prior to hospital discharge in a patient who has been adequately revascularized</li> </ul>	I (1)
<b>Cardiac Rehabilitation With Stress Echocardiography</b>	
168. <ul style="list-style-type: none"> <li>• Prior to initiation of cardiac rehabilitation (as a stand-alone indication)</li> </ul>	I (3)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 15** Stress echocardiography for risk assessment: Postrevascularization (PCI or CABG)

Indication	Appropriate use score (1–9)
<b>Symptomatic With Stress Echocardiography</b>	
169. <ul style="list-style-type: none"> <li>• Ischemic equivalent</li> </ul>	A (8)
<b>Asymptomatic With Stress Echocardiography</b>	
170. <ul style="list-style-type: none"> <li>• Incomplete revascularization</li> <li>• Additional revascularization feasible</li> </ul>	A (7)
171. <ul style="list-style-type: none"> <li>• &lt;5 y after CABG</li> </ul>	I (2)
172. <ul style="list-style-type: none"> <li>• ≥5 y after CABG</li> </ul>	U (6)
173. <ul style="list-style-type: none"> <li>• &lt;2 y after PCI</li> </ul>	I (2)
174. <ul style="list-style-type: none"> <li>• ≥2 y after PCI</li> </ul>	U (5)
<b>Cardiac Rehabilitation With Stress Echocardiography</b>	
175. <ul style="list-style-type: none"> <li>• Prior to initiation of cardiac rehabilitation (as a stand-alone indication)</li> </ul>	I (3)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 16** Stress echocardiography for assessment of viability/ischemia

Indication	Appropriate use score (1–9)
<b>Ischemic Cardiomyopathy/Assessment of Viability With Stress Echocardiography</b>	
176. <ul style="list-style-type: none"> <li>• Known moderate or severe LV dysfunction</li> <li>• Patient eligible for revascularization</li> <li>• Use of dobutamine stress only</li> </ul>	A (8)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 17** Stress echocardiography for hemodynamics (includes doppler during stress)

Indication	Appropriate use score (1–9)
<b>Chronic Valvular Disease—Asymptomatic With Stress Echocardiography</b>	
177. ● Mild mitral stenosis	I (2)
178. ● Moderate mitral stenosis	U (5)
179. ● Severe mitral stenosis	A (7)
180. ● Mild aortic stenosis	I (3)
181. ● Moderate aortic stenosis	U (6)
182. ● Severe aortic stenosis	U (5)
183. ● Mild mitral regurgitation	I (2)
184. ● Moderate mitral regurgitation	U (5)
185. ● Severe mitral regurgitation ● LV size and function not meeting surgical criteria	A (7)
186. ● Mild aortic regurgitation	I (2)
187. ● Moderate aortic regurgitation	U (5)
188. ● Severe aortic regurgitation ● LV size and function not meeting surgical criteria	A (7)
<b>Chronic Valvular Disease—Symptomatic With Stress Echocardiography</b>	
189. ● Mild mitral stenosis	U (5)
190. ● Moderate mitral stenosis	A (7)
191. ● Severe mitral stenosis	I (3)
192. ● Severe aortic stenosis	I (1)
193. ● Evaluation of equivocal aortic stenosis ● Evidence of low cardiac output or LV systolic dysfunction (“low gradient aortic stenosis”) ● Use of dobutamine only	A (8)
194. ● Mild mitral regurgitation	U (4)
195. ● Moderate mitral regurgitation	A (7)
196. ● Severe mitral regurgitation ● Severe LV enlargement or LV systolic dysfunction	I (3)
<b>Acute Valvular Disease With Stress Echocardiography</b>	
197. ● Acute moderate or severe mitral or aortic regurgitation	I (3)
<b>Pulmonary Hypertension With Stress Echocardiography</b>	
198. ● Suspected pulmonary artery hypertension ● Normal or borderline elevated estimated right ventricular systolic pressure on resting echocardiographic study	U (5)
199. ● Routine evaluation of patients with known resting pulmonary hypertension	I (3)
200. ● Re-evaluation of patient with exercise-induced pulmonary hypertension to evaluate response to therapy	U (5)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 18** Contrast use in TTE/TEE or stress echocardiography

Indication	Appropriate use score (1–9)
201. ● Routine use of contrast ● All LV segments visualized on noncontrast images	I (1)
202. ● Selective use of contrast ● ≥2 contiguous LV segments are not seen on noncontrast images	A (8)

A indicates appropriate; I, inappropriate; U, uncertain.

**7. ECHOCARDIOGRAPHY APPROPRIATE USE CRITERIA (BY APPROPRIATE USE RATING)****Table 19** Appropriate indications (median score 7–9)

Indication	Appropriate use score (1–9)
<b>TTE for General Evaluation of Cardiac Structure and Function Suspected Cardiac Etiology—General</b>	
1. • Symptoms or conditions potentially related to suspected cardiac etiology including but not limited to chest pain, shortness of breath, palpitations, TIA, stroke, or peripheral embolic event	A (9)
2. • Prior testing that is concerning for heart disease or structural abnormality including but not limited to chest X-ray, baseline scout images for stress echocardiogram, ECG, or cardiac biomarkers	A (9)
<b>TTE for General Evaluation of Cardiac Structure and Function Arrhythmias</b>	
4. • Frequent VPCs or exercise-induced VPCs	A (8)
5. • Sustained or nonsustained atrial fibrillation, SVT, or VT	A (9)
<b>TTE for General Evaluation of Cardiac Structure and Function Lightheadedness/Presyncope/Syncope</b>	
7. • Clinical symptoms or signs consistent with a cardiac diagnosis known to cause lightheadedness/presyncope/syncope (including but not limited to aortic stenosis, hypertrophic cardiomyopathy, or HF)	A (9)
9. • Syncope when there are no other symptoms or signs of cardiovascular disease	A (7)
<b>TTE for General Evaluation of Cardiac Structure and Function Pulmonary Hypertension</b>	
15. • Evaluation of suspected pulmonary hypertension including evaluation of right ventricular function and estimated pulmonary artery pressure	A (9)
17. • Routine surveillance ( $\geq 1$ y) of known pulmonary hypertension without change in clinical status or cardiac exam	A (7)
18. • Re-evaluation of known pulmonary hypertension if change in clinical status or cardiac exam or to guide therapy	A (9)
<b>TTE for Cardiovascular Evaluation in an Acute Setting Hypotension or Hemodynamic Instability</b>	
19. • Hypotension or hemodynamic instability of uncertain or suspected cardiac etiology	A (9)
<b>TTE for Cardiovascular Evaluation in an Acute Setting Myocardial Ischemia/Infarction</b>	
21. • Acute chest pain with suspected MI and nondiagnostic ECG when a resting echocardiogram can be performed during pain	A (9)
22. • Evaluation of a patient without chest pain but with other features of an ischemic equivalent or laboratory markers indicative of ongoing MI	A (8)
23. • Suspected complication of myocardial ischemia/infarction, including but not limited to acute mitral regurgitation, ventricular septal defect, free-wall rupture/tamponade, shock, right ventricular involvement, HF, or thrombus	A (9)
<b>TTE for Cardiovascular Evaluation in an Acute Setting Evaluation of Ventricular Function after ACS</b>	
24. • Initial evaluation of ventricular function following ACS	A (9)
25. • Re-evaluation of ventricular function following ACS during recovery phase when results will guide therapy	A (9)
<b>TTE for Cardiovascular Evaluation in an Acute Setting Respiratory Failure</b>	
26. • Respiratory failure or hypoxemia of uncertain etiology	A (8)
<b>TTE for Cardiovascular Evaluation in an Acute Setting Pulmonary Embolism</b>	
29. • Known acute pulmonary embolism to guide therapy (e.g., thrombectomy and thrombolytics)	A (8)
31. • Re-evaluation of known pulmonary embolism after thrombolysis or thrombectomy for assessment of change in right ventricular function and/or pulmonary artery pressure	A (7)
<b>TTE for Cardiovascular Evaluation in an Acute Setting Cardiac Trauma</b>	
32. • Severe deceleration injury or chest trauma when valve injury, pericardial effusion, or cardiac injury are possible or suspected	A (9)
<b>TTE for Evaluation of Valvular Function Murmur or Click</b>	
34. • Initial evaluation when there is a reasonable suspicion of valvular or structural heart disease	A (9)
37. • Re-evaluation of known valvular heart disease with a change in clinical status or cardiac exam or to guide therapy	A (9)
<b>TTE for Evaluation of Valvular Function Native Valvular Stenosis</b>	
39. • Routine surveillance ( $\geq 3$ y) of mild valvular stenosis without a change in clinical status or cardiac exam	A (7)

(Continued)

**Table 19** (Continued)

Indication	Appropriate use score (1–9)
41. • Routine surveillance ( $\geq 1$ y) of moderate or severe valvular stenosis without a change in clinical status or cardiac exam	A (8)
46. • Routine surveillance ( $\geq 1$ y) of moderate or severe valvular regurgitation without change in clinical status or cardiac exam	A (8)
<b>TTE for Evaluation of Valvular Function Prosthetic Valves</b>	
47. • Initial postoperative evaluation of prosthetic valve for establishment of baseline	A (9)
49. • Routine surveillance ( $\geq 3$ y after valve implantation) of prosthetic valve if no known or suspected valve dysfunction	A (7)
50. • Evaluation of prosthetic valve with suspected dysfunction or a change in clinical status or cardiac exam	A (9)
51. • Re-evaluation of known prosthetic valve dysfunction when it would change management or guide therapy	A (9)
<b>TTE for Evaluation of Valvular Function Infective Endocarditis (Native or Prosthetic Valves)</b>	
52. • Initial evaluation of suspected infective endocarditis with positive blood cultures or a new murmur	A (9)
55. • Re-evaluation of infective endocarditis at high risk for progression or complication or with a change in clinical status or cardiac exam	A (9)
<b>TTE for Evaluation of Intracardiac and Extracardiac Structures and Chambers</b>	
57. • Suspected cardiac mass	A (9)
58. • Suspected cardiovascular source of embolus	A (9)
59. • Suspected pericardial conditions	A (9)
61. • Re-evaluation of known pericardial effusion to guide management or therapy	A (8)
62. • Guidance of percutaneous noncoronary cardiac procedures including but not limited to pericardiocentesis, septal ablation, or right ventricular biopsy	A (9)
<b>TTE for Evaluation of Aortic Disease</b>	
63. • Evaluation of the ascending aorta in the setting of a known or suspected connective tissue disease or genetic condition that predisposes to aortic aneurysm or dissection (e.g., Marfan syndrome)	A (9)
64. • Re-evaluation of known ascending aortic dilation or history of aortic dissection to establish a baseline rate of expansion or when the rate of expansion is excessive	A (9)
65. • Re-evaluation of known ascending aortic dilation or history of aortic dissection with a change in clinical status or cardiac exam or when findings may alter management or therapy	A (9)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy Hypertension</b>	
67. • Initial evaluation of suspected hypertensive heart disease	A (8)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy HF</b>	
70. • Initial evaluation of known or suspected HF (systolic or diastolic) based on symptoms, signs, or abnormal test results	A (9)
71. • Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac exam without a clear precipitating change in medication or diet	A (8)
73. • Re-evaluation of known HF (systolic or diastolic) to guide therapy	A (9)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy Device Evaluation (Including Pacemaker, ICD, or CRT)</b>	
76. • Initial evaluation or re-evaluation after revascularization and/or optimal medical therapy to determine candidacy for device therapy and/or to determine optimal choice of device	A (9)
78. • Known implanted pacing device with symptoms possibly due to device complication or suboptimal pacing device settings	A (8)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy Ventricular Assist Devices and Cardiac Transplantation</b>	
81. • To determine candidacy for ventricular assist device	A (9)
82. • Optimization of ventricular assist device settings	A (7)
83. • Re-evaluation for signs/symptoms suggestive of ventricular assist device-related complications	A (9)
84. • Monitoring for rejection in a cardiac transplant recipient	A (7)
85. • Cardiac structure and function evaluation in a potential heart donor	A (9)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy Cardiomyopathies</b>	
86. • Initial evaluation of known or suspected cardiomyopathy (e.g., restrictive, infiltrative, dilated, hypertrophic, or genetic cardiomyopathy)	A (9)
87. • Re-evaluation of known cardiomyopathy with a change in clinical status or cardiac exam or to guide therapy	A (9)

(Continued)

Table 19 (Continued)

Indication	Appropriate use score (1–9)
90. • Screening evaluation for structure and function in first-degree relatives of a patient with an inherited cardiomyopathy	A (9)
91. • Baseline and serial re-evaluations in a patient undergoing therapy with cardiotoxic agents	A (9)
<b>TTE for Adult Congenital Heart Disease</b>	
92. • Initial evaluation of known or suspected adult congenital heart disease	A (9)
93. • Known adult congenital heart disease with a change in clinical status or cardiac exam	A (9)
94. • Re-evaluation to guide therapy in known adult congenital heart disease	A (9)
98. • Routine surveillance ( $\geq 1$ y) of adult congenital heart disease following incomplete or palliative repair <ul style="list-style-type: none"> <li>◦ with residual structural or hemodynamic abnormality</li> <li>◦ without a change in clinical status or cardiac exam</li> </ul>	A (8)
<b>TEE as Initial or Supplemental Test—General Uses</b>	
99. • Use of TEE when there is a high likelihood of a nondiagnostic TTE due to patient characteristics or inadequate visualization of relevant structures	A (8)
101. • Re-evaluation of prior TEE finding for interval change (e.g., resolution of thrombus after anticoagulation, resolution of vegetation after antibiotic therapy) when a change in therapy is anticipated	A (8)
103. • Guidance during percutaneous noncoronary cardiac interventions including but not limited to closure device placement, radiofrequency ablation, and percutaneous valve procedures	A (9)
104. • Suspected acute aortic pathology including but not limited to dissection/transsection	A (9)
<b>TEE as Initial or Supplemental Test—Valvular Disease</b>	
106. • Evaluation of valvular structure and function to assess suitability for, and assist in planning of, an intervention	A (9)
108. • To diagnose infective endocarditis with a moderate or high pretest probability (e.g., staph bacteremia, fungemia, prosthetic heart valve, or intracardiac device)	A (9)
<b>TEE as Initial or Supplemental Test—Embolitic Event</b>	
109. • Evaluation for cardiovascular source of embolus with no identified noncardiac source	A (7)
<b>TEE as Initial Test—Atrial Fibrillation/Flutter</b>	
112. • Evaluation to facilitate clinical decision making with regards to anticoagulation, cardioversion, and/or radiofrequency ablation	A (9)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent Evaluation of Ischemic Equivalent (Nonacute)</b>	
115. • Low pretest probability of CAD • ECG uninterpretable or unable to exercise	A (7)
116. • Intermediate pretest probability of CAD • ECG interpretable and able to exercise	A (7)
117. • Intermediate pretest probability of CAD • ECG uninterpretable or unable to exercise	A (9)
118. • High pretest probability of CAD • Regardless of ECG interpretability and ability to exercise	A (7)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent Acute Chest Pain</b>	
119. • Possible ACS • ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm • Low-risk TIMI score • Negative troponin levels	A (7)
120. • Possible ACS • ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm • Low-risk TIMI score • Peak troponin: borderline, equivocal, minimally elevated	A (7)
121. • Possible ACS • ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm • High-risk TIMI score • Negative troponin levels	A (7)
122. • Possible ACS • ECG: no ischemic changes or with LBBB or electronically paced ventricular rhythm • High-risk TIMI score • Peak troponin: borderline, equivocal, minimally elevated	A (7)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities New-Onset or Newly Diagnosed HF or LV Systolic Dysfunction</b>	
128. • No prior CAD evaluation and no planned coronary angiography	A (7)

(Continued)

**Table 19** (Continued)

Indication	Appropriate use score (1–9)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities Arrhythmias</b>	
129. • Sustained VT	A (7)
130. • Frequent PVCs, exercise-induced VT, or nonsustained VT	A (7)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities Syncope</b>	
134. • Intermediate or high global CAD risk	A (7)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities Elevated Troponin</b>	
135. • Troponin elevation without symptoms or additional evidence of ACS	A (7)
<b>Stress Echocardiography Following Prior Test Results Asymptomatic: Prior Evidence of Subclinical Disease</b>	
139. • Coronary calcium Agatston score >400	A (7)
<b>Stress Echocardiography Following Prior Test Results Coronary Angiography (Invasive or Noninvasive)</b>	
141. • Coronary artery stenosis of unclear significance	A (8)
<b>Stress Echocardiography Following Prior Test Results Treadmill ECG Stress Test</b>	
149. • Intermediate-risk treadmill score (e.g., Duke)	A (7)
150. • High-risk treadmill score (e.g., Duke)	A (7)
<b>Stress Echocardiography Following Prior Test Results New or Worsening Symptoms</b>	
151. • Abnormal coronary angiography or abnormal prior stress imaging study	A (7)
<b>Stress Echocardiography Following Prior Test Results Prior Noninvasive Evaluation</b>	
153. • Equivocal, borderline, or discordant stress testing where obstructive CAD remains a concern	A (8)
<b>Stress Echocardiography for Risk Assessment: Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions Vascular Surgery</b>	
161. • $\geq 1$ clinical risk factor • Poor or unknown functional capacity (<4 METs)	A (7)
<b>Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS STEMI</b>	
164. • Hemodynamically stable, no recurrent chest pain symptoms, or no signs of HF • To evaluate for inducible ischemia • No prior coronary angiography since the index event	A (7)
<b>Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS UA/NSTEMI</b>	
166. • Hemodynamically stable, no recurrent chest pain symptoms, or no signs of HF • To evaluate for inducible ischemia • No prior coronary angiography since the index event	A (8)
<b>Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG) Symptomatic</b>	
169. • Ischemic equivalent	A (8)
<b>Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG) Asymptomatic</b>	
170. • Incomplete revascularization • Additional revascularization feasible	A (7)
<b>Stress Echocardiography for Assessment of Viability/Ischemia Ischemic Cardiomyopathy/Assessment of Viability</b>	
176. • Known moderate or severe LV dysfunction • Patient eligible for revascularization • Use of dobutamine stress only	A (8)
<b>Stress Echocardiography for Hemodynamics (Includes Doppler During Stress) Chronic Valvular Disease—Asymptomatic</b>	
179. • Severe mitral stenosis	A (7)
185. • Severe mitral regurgitation • LV size and function not meeting surgical criteria	A (7)
188. • Severe aortic regurgitation • LV size and function not meeting surgical criteria	A (7)
<b>Stress Echocardiography for Hemodynamics (Includes Doppler During Stress) Chronic Valvular Disease—Symptomatic</b>	
190. • Moderate mitral stenosis	A (7)
193. • Evaluation of equivocal aortic stenosis • Evidence of low cardiac output or LV systolic dysfunction (“low gradient aortic stenosis”) • Use of dobutamine only	A (8)
195. • Moderate mitral regurgitation	A (7)
<b>Contrast Use in TTE/TEE or Stress Echocardiography</b>	
202. • Selective use of contrast • $\geq 2$ contiguous LV segments are not seen on noncontrast images	A (8)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 20** Uncertain indications (median score 4–6)

Indication	Appropriate use score (1–9)
<b>TTE for General Evaluation of Cardiac Structure and Function Perioperative Evaluation</b>	
14. • Routine perioperative evaluation of cardiac structure and function prior to noncardiac solid organ transplantation	U (6)
<b>TTE for Cardiovascular Evaluation in an Acute Setting Hypotension or Hemodynamic Instability</b>	
20. • Assessment of volume status in a critically ill patient	U (5)
<b>TTE for Cardiovascular Evaluation in an Acute Setting Respiratory Failure</b>	
27. • Respiratory failure or hypoxemia when a noncardiac etiology of respiratory failure has been established	U (5)
<b>TTE for Evaluation of Valvular Function Native Valvular Regurgitation</b>	
44. • Routine surveillance ( $\geq 3$ y) of mild valvular regurgitation without a change in clinical status or cardiac exam	U (4)
45. • Routine surveillance ( $< 1$ y) of moderate or severe valvular regurgitation without a change in clinical status or cardiac exam	U (6)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy Hypertension</b>	
69. • Re-evaluation of known hypertensive heart disease without a change in clinical status or cardiac exam	U (4)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy HF</b>	
72. • Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac exam with a clear precipitating change in medication or diet	U (4)
75. • Routine surveillance ( $\geq 1$ y) of HF (systolic or diastolic) when there is no change in clinical status or cardiac exam	U (6)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy Device Evaluation (Including Pacemaker, ICD, or CRT)</b>	
77. • Initial evaluation for CRT device optimization after implantation	U (6)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy Cardiomyopathies</b>	
89. • Routine surveillance ( $\geq 1$ y) of known cardiomyopathy without a change in clinical status or cardiac exam	U (5)
<b>TTE for Adult Congenital Heart Disease</b>	
96. • Routine surveillance ( $\geq 2$ y) of adult congenital heart disease following complete repair <ul style="list-style-type: none"> <li>◦ without residual structural or hemodynamic abnormality</li> <li>◦ without a change in clinical status or cardiac exam</li> </ul>	U (6)
97. • Routine surveillance ( $< 1$ y) of adult congenital heart disease following incomplete or palliative repair <ul style="list-style-type: none"> <li>◦ with residual structural or hemodynamic abnormality</li> <li>◦ without a change in clinical status or cardiac exam</li> </ul>	U (5)
<b>TEE as Initial or Supplemental Test—Embolic Event</b>	
110. • Evaluation for cardiovascular source of embolus with a previously identified noncardiac source	U (5)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) General Patient Populations</b>	
126. • Intermediate global CAD risk • ECG uninterpretable	U (5)
127. • High global CAD risk	U (5)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities Arrhythmias</b>	
132. • New-onset atrial fibrillation	U (6)
<b>Stress Echocardiography Following Prior Test Results Asymptomatic: Prior Evidence of Subclinical Disease</b>	
137. • Low to intermediate global CAD risk • Coronary calcium Agatston score between 100 and 400	U (5)
138. • High global CAD risk • Coronary calcium Agatston score between 100 and 400	U (6)
140. • Abnormal carotid intimal medial thickness ( $\geq 0.9$ mm and/or the presence of plaque encroaching into the arterial lumen)	U (5)
<b>Stress Echocardiography Following Prior Test Results Asymptomatic or Stable Symptoms Normal Prior Stress Imaging Study</b>	
145. • Intermediate to high global CAD risk • Last stress imaging study $\geq 2$ y ago	U (4)

(Continued)

**Table 20** (Continued)

Indication	Appropriate use score (1–9)
<b>Stress Echocardiography Following Prior Test Results Asymptomatic or Stable Symptoms Abnormal Coronary Angiography or Abnormal Prior Stress Study No Prior Revascularization</b>	
147. <ul style="list-style-type: none"> <li>• Known CAD on coronary angiography or prior abnormal stress imaging study</li> <li>• Last stress imaging study <math>\geq 2</math> y ago</li> </ul>	U (5)
<b>Stress Echocardiography Following Prior Test Results New or Worsening Symptoms</b>	
152. <ul style="list-style-type: none"> <li>• Normal coronary angiography or normal prior stress imaging study</li> </ul>	U (6)
<b>Stress Echocardiography for Risk Assessment: Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions Intermediate-Risk Surgery</b>	
157. <ul style="list-style-type: none"> <li>• <math>\geq 1</math> clinical risk factor</li> <li>• Poor or unknown functional capacity (<math>&lt; 4</math> METs)</li> </ul>	U (6)
<b>Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG) Asymptomatic</b>	
172. <ul style="list-style-type: none"> <li>• <math>\geq 5</math> y after CABG</li> </ul>	U (6)
174. <ul style="list-style-type: none"> <li>• <math>\geq 2</math> y after PCI</li> </ul>	U (5)
<b>Stress Echocardiography for Hemodynamics (Includes Doppler During Stress) Chronic Valvular Disease—Asymptomatic</b>	
178. <ul style="list-style-type: none"> <li>• Moderate mitral stenosis</li> </ul>	U (5)
181. <ul style="list-style-type: none"> <li>• Moderate aortic stenosis</li> </ul>	U (6)
182. <ul style="list-style-type: none"> <li>• Severe aortic stenosis</li> </ul>	U (5)
184. <ul style="list-style-type: none"> <li>• Moderate mitral regurgitation</li> </ul>	U (5)
187. <ul style="list-style-type: none"> <li>• Moderate aortic regurgitation</li> </ul>	U (5)
<b>Stress Echocardiography for Hemodynamics (Includes Doppler During Stress) Chronic Valvular Disease—Symptomatic</b>	
189. <ul style="list-style-type: none"> <li>• Mild mitral stenosis</li> </ul>	U (5)
194. <ul style="list-style-type: none"> <li>• Mild mitral regurgitation</li> </ul>	U (4)
<b>Stress Echocardiography for Hemodynamics (Includes Doppler During Stress) Pulmonary Hypertension</b>	
198. <ul style="list-style-type: none"> <li>• Suspected pulmonary hypertension</li> <li>• Normal or borderline elevated estimated right ventricular systolic pressure on resting echocardiographic study</li> </ul>	U (5)
200. <ul style="list-style-type: none"> <li>• Re-evaluation of patient with exercise-induced pulmonary hypertension to evaluate response to therapy</li> </ul>	U (5)

A indicates appropriate; I, inappropriate; U, uncertain.

**Table 21** Inappropriate indications (median score 1–3)

Indication	Appropriate use score (1–9)
<b>TTE for General Evaluation of Cardiac Structure and Function Arrhythmias</b>	
3. <ul style="list-style-type: none"> <li>• Infrequent APCs or infrequent VPCs without other evidence of heart disease</li> </ul>	I (2)
6. <ul style="list-style-type: none"> <li>• Asymptomatic isolated sinus bradycardia</li> </ul>	I (2)
<b>TTE for General Evaluation of Cardiac Structure and Function Lightheadedness/Presyncope/Syncope</b>	
8. <ul style="list-style-type: none"> <li>• Lightheadedness/presyncope when there are no other symptoms or signs of cardiovascular disease</li> </ul>	I (3)
<b>TTE for General Evaluation of Cardiac Structure and Function Evaluation of Ventricular Function</b>	
10. <ul style="list-style-type: none"> <li>• Initial evaluation of ventricular function (e.g., screening) with no symptoms or signs of cardiovascular disease</li> </ul>	I (2)
11. <ul style="list-style-type: none"> <li>• Routine surveillance of ventricular function with known CAD and no change in clinical status or cardiac exam</li> </ul>	I (3)
12. <ul style="list-style-type: none"> <li>• Evaluation of LV function with prior ventricular function evaluation showing normal function (e.g., prior echocardiogram, left ventriculogram, CT, SPECT MPI, CMR) in patients in whom there has been no change in clinical status or cardiac exam</li> </ul>	I (1)
<b>TTE for General Evaluation of Cardiac Structure and Function Perioperative Evaluation</b>	
13. <ul style="list-style-type: none"> <li>• Routine perioperative evaluation of ventricular function with no symptoms or signs of cardiovascular disease</li> </ul>	I (2)

(Continued)

**Table 21** (Continued)

Indication	Appropriate use score (1–9)
<b>TTE for General Evaluation of Cardiac Structure and Function Pulmonary Hypertension</b>	
16. • Routine surveillance (<1 y) of known pulmonary hypertension without change in clinical status or cardiac exam	I (3)
<b>TTE for Cardiovascular Evaluation in an Acute Setting Pulmonary Embolism</b>	
28. • Suspected pulmonary embolism in order to establish diagnosis	I (2)
30. • Routine surveillance of prior pulmonary embolism with normal right ventricular function and pulmonary artery systolic pressure	I (1)
<b>TTE for Cardiovascular Evaluation in an Acute Setting Cardiac Trauma</b>	
33. • Routine evaluation in the setting of mild chest trauma with no electrocardiographic changes or biomarker elevation	I (2)
<b>TTE for Evaluation of Valvular Function Murmur or Click</b>	
35. • Initial evaluation when there are no other symptoms or signs of valvular or structural heart disease	I (2)
36. • Re-evaluation in a patient without valvular disease on prior echocardiogram and no change in clinical status or cardiac exam	I (1)
<b>TTE for Evaluation of Valvular Function Native Valvular Stenosis</b>	
38. • Routine surveillance (<3 y) of mild valvular stenosis without a change in clinical status or cardiac exam	I (3)
40. • Routine surveillance (<1 y) of moderate or severe valvular stenosis without a change in clinical status or cardiac exam	I (3)
<b>TTE for Evaluation of Valvular Function Native Valvular Regurgitation</b>	
42. • Routine surveillance of trace valvular regurgitation	I (1)
43. • Routine surveillance (<3 y) of mild valvular regurgitation without a change in clinical status or cardiac exam	I (2)
<b>TTE for Evaluation of Valvular Function Prosthetic Valves</b>	
48. • Routine surveillance (<3 y after valve implantation) of prosthetic valve if no known or suspected valve dysfunction	I (3)
<b>TTE for Evaluation of Valvular Function Infective Endocarditis (Native or Prosthetic Valves)</b>	
53. • Transient fever without evidence of bacteremia or a new murmur	I (2)
54. • Transient bacteremia with a pathogen not typically associated with infective endocarditis and/or a documented nonendovascular source of infection	I (3)
56. • Routine surveillance of uncomplicated infective endocarditis when no change in management is contemplated	I (2)
<b>TTE for Evaluation of Intracardiac and Extracardiac Structures and Chambers</b>	
60. • Routine surveillance of known small pericardial effusion with no change in clinical status	I (2)
<b>TTE for Evaluation of Aortic Disease</b>	
66. • Routine re-evaluation for surveillance of known ascending aortic dilation or history of aortic dissection without a change in clinical status or cardiac exam when findings would not change management or therapy	I (3)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy Hypertension</b>	
68. • Routine evaluation of systemic hypertension without symptoms or signs of hypertensive heart disease	I (3)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy HF</b>	
74. • Routine surveillance (<1 y) of HF (systolic or diastolic) when there is no change in clinical status or cardiac exam	I (2)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy Device Evaluation (Including Pacemaker, ICD, or CRT)</b>	
79. • Routine surveillance (<1 y) of implanted device without a change in clinical status or cardiac exam	I (1)
80. • Routine surveillance ( $\geq 1$ y) of implanted device without a change in clinical status or cardiac exam	I (3)
<b>TTE for Evaluation of Hypertension, HF, or Cardiomyopathy Cardiomyopathies</b>	

(Continued)

**Table 21** (Continued)

Indication	Appropriate use score (1–9)
88. <ul style="list-style-type: none"> <li>• Routine surveillance (&lt;1 y) of known cardiomyopathy without a change in clinical status or cardiac exam</li> </ul>	I (2)
<b>TTE for Adult Congenital Heart Disease</b>	
95. <ul style="list-style-type: none"> <li>• Routine surveillance (&lt;2 y) of adult congenital heart disease following complete repair <ul style="list-style-type: none"> <li>◦ without a residual structural or hemodynamic abnormality</li> <li>◦ without a change in clinical status or cardiac exam</li> </ul> </li> </ul>	I (3)
<b>TEE as Initial or Supplemental Test—General Uses</b>	
100. <ul style="list-style-type: none"> <li>• Routine use of TEE when a diagnostic TTE is reasonably anticipated to resolve all diagnostic and management concerns</li> </ul>	I (1)
102. <ul style="list-style-type: none"> <li>• Surveillance of prior TEE finding for interval change (e.g., resolution of thrombus after anticoagulation, resolution of vegetation after antibiotic therapy) when no change in therapy is anticipated</li> </ul>	I (2)
105. <ul style="list-style-type: none"> <li>• Routine assessment of pulmonary veins in an asymptomatic patient status post pulmonary vein isolation</li> </ul>	I (3)
<b>TEE as Initial or Supplemental Test—Valvular Disease</b>	
107. <ul style="list-style-type: none"> <li>• To diagnose infective endocarditis with a low pretest probability (e.g., transient fever, known alternative source of infection, or negative blood cultures/atypical pathogen for endocarditis)</li> </ul>	I (3)
<b>TEE as Initial or Supplemental Test—Embolitic Event</b>	
111. <ul style="list-style-type: none"> <li>• Evaluation for cardiovascular source of embolus with a known cardiac source in which a TEE would not change management</li> </ul>	I (1)
<b>TEE as Initial Test—Atrial Fibrillation/Flutter</b>	
113. <ul style="list-style-type: none"> <li>• Evaluation when a decision has been made to anticoagulate and not to perform cardioversion</li> </ul>	I (2)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent Evaluation of Ischemic Equivalent (Nonacute)</b>	
114. <ul style="list-style-type: none"> <li>• Low pretest probability of CAD</li> <li>• ECG interpretable and able to exercise</li> </ul>	I (3)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Symptomatic or Ischemic Equivalent Acute Chest Pain</b>	
123. <ul style="list-style-type: none"> <li>• Definite ACS</li> </ul>	I (1)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) General Patient Populations</b>	
124. <ul style="list-style-type: none"> <li>• Low global CAD risk</li> </ul>	I (1)
125. <ul style="list-style-type: none"> <li>• Intermediate global CAD risk</li> <li>• ECG interpretable</li> </ul>	I (2)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities Arrhythmias</b>	
131. <ul style="list-style-type: none"> <li>• Infrequent PVCs</li> </ul>	I (3)
<b>Stress Echocardiography for Detection of CAD/Risk Assessment: Asymptomatic (Without Ischemic Equivalent) in Patient Populations With Defined Comorbidities Syncope</b>	
133. <ul style="list-style-type: none"> <li>• Low global CAD risk</li> </ul>	I (3)
<b>Stress Echocardiography Following Prior Test Results Asymptomatic: Prior Evidence of Subclinical Disease</b>	
136. <ul style="list-style-type: none"> <li>• Coronary calcium Agatston score &lt;100</li> </ul>	I (2)
<b>Stress Echocardiography Following Prior Test Results Asymptomatic or Stable Symptoms Normal Prior Stress Imaging Study</b>	
142. <ul style="list-style-type: none"> <li>• Low global CAD risk</li> <li>• Last stress imaging study &lt;2 y ago</li> </ul>	I (1)
143. <ul style="list-style-type: none"> <li>• Low global CAD risk</li> <li>• Last stress imaging study ≥2 y ago</li> </ul>	I (2)
144. <ul style="list-style-type: none"> <li>• Intermediate to high global CAD risk</li> <li>• Last stress imaging study &lt;2 y ago</li> </ul>	I (2)

(Continued)

Table 21 (Continued)


Indication	Appropriate use score (1–9)
<b>Stress Echocardiography Following Prior Test Results Asymptomatic or Stable Symptoms Abnormal Coronary Angiography or Abnormal Prior Stress Study No Prior Revascularization</b>	
146. <ul style="list-style-type: none"> <li>• Known CAD on coronary angiography or prior abnormal stress imaging study</li> <li>• Last stress imaging study &lt;2 y ago</li> </ul>	I (3)
<b>Stress Echocardiography Following Prior Test Results Treadmill ECG Stress Test</b>	
148. <ul style="list-style-type: none"> <li>• Low-risk treadmill score (e.g., Duke)</li> </ul>	I (1)
<b>Stress Echocardiography for Risk Assessment: Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions Low-Risk Surgery</b>	
154. <ul style="list-style-type: none"> <li>• Perioperative evaluation for risk assessment</li> </ul>	I (1)
<b>Stress Echocardiography for Risk Assessment: Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions Intermediate-Risk Surgery</b>	
155. <ul style="list-style-type: none"> <li>• Moderate to good functional capacity (<math>\geq 4</math> METs)</li> </ul>	I (3)
156. <ul style="list-style-type: none"> <li>• No clinical risk factors</li> </ul>	I (2)
158. <ul style="list-style-type: none"> <li>• Asymptomatic &lt;1 y post normal catheterization, noninvasive test, or previous revascularization</li> </ul>	I (1)
<b>Stress Echocardiography for Risk Assessment: Perioperative Evaluation for Noncardiac Surgery Without Active Cardiac Conditions Vascular Surgery</b>	
159. <ul style="list-style-type: none"> <li>• Moderate to good functional capacity (<math>\geq 4</math> METs)</li> </ul>	I (3)
160. <ul style="list-style-type: none"> <li>• No clinical risk factors</li> </ul>	I (2)
162. <ul style="list-style-type: none"> <li>• Asymptomatic &lt;1 y post normal catheterization, noninvasive test, or previous revascularization</li> </ul>	I (2)
<b>Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS STEMI</b>	
163. <ul style="list-style-type: none"> <li>• Primary PCI with complete revascularization</li> <li>• No recurrent symptoms</li> </ul>	I (2)
165. <ul style="list-style-type: none"> <li>• Hemodynamically unstable, signs of cardiogenic shock, or mechanical complications</li> </ul>	I (1)
<b>Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS ACS—Asymptomatic Postrevascularization (PCI or CABG)</b>	
167. <ul style="list-style-type: none"> <li>• Prior to hospital discharge in a patient who has been adequately revascularized</li> </ul>	I (1)
<b>Stress Echocardiography for Risk Assessment: Within 3 Months of an ACS Cardiac Rehabilitation</b>	
168. <ul style="list-style-type: none"> <li>• Prior to initiation of cardiac rehabilitation (as a stand-alone indication)</li> </ul>	I (3)
<b>Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG) Asymptomatic</b>	
171. <ul style="list-style-type: none"> <li>• &lt;5 y after CABG</li> </ul>	I (2)
173. <ul style="list-style-type: none"> <li>• &lt;2 y after PCI</li> </ul>	I (2)
<b>Stress Echocardiography for Risk Assessment: Postrevascularization (PCI or CABG) Cardiac Rehabilitation</b>	
175. <ul style="list-style-type: none"> <li>• Prior to initiation of cardiac rehabilitation (as a stand-alone indication)</li> </ul>	I (3)
<b>Stress Echocardiography for Hemodynamics (Includes Doppler During Stress) Chronic Valvular Disease—Asymptomatic</b>	
177. <ul style="list-style-type: none"> <li>• Mild mitral stenosis</li> </ul>	I (2)
180. <ul style="list-style-type: none"> <li>• Mild aortic stenosis</li> </ul>	I (3)
183. <ul style="list-style-type: none"> <li>• Mild mitral regurgitation</li> </ul>	I (2)
186. <ul style="list-style-type: none"> <li>• Mild aortic regurgitation</li> </ul>	I (2)
<b>Stress Echocardiography for Hemodynamics (Includes Doppler During Stress) Chronic Valvular Disease—Symptomatic</b>	
191. <ul style="list-style-type: none"> <li>• Severe mitral stenosis</li> </ul>	I (3)
192. <ul style="list-style-type: none"> <li>• Severe aortic stenosis</li> </ul>	I (1)
196. <ul style="list-style-type: none"> <li>• Severe mitral regurgitation</li> <li>• Severe LV enlargement or LV systolic dysfunction</li> </ul>	I (3)
<b>Stress Echocardiography for Hemodynamics (Includes Doppler During Stress) Acute Valvular disease</b>	

(Continued)

**Table 21** (Continued)

Indication	Appropriate use score (1–9)
197. <ul style="list-style-type: none"> <li>• Acute moderate or severe mitral or aortic regurgitation</li> </ul>	I (3)
<b>Stress Echocardiography for Hemodynamics (Includes Doppler During Stress) Pulmonary Hypertension</b>	
199. <ul style="list-style-type: none"> <li>• Routine evaluation of patients with known resting pulmonary hypertension</li> </ul>	I (3)
<b>Contrast Use in TTE/TEE or Stress Echocardiography</b>	
201. <ul style="list-style-type: none"> <li>• Routine use of contrast</li> <li>• All LV segments visualized on noncontrast images</li> </ul>	I (1)

A indicates appropriate; I, inappropriate; U, uncertain.



**Figure 1** Stress echocardiography for detection of CAD/Risk assessment: Symptomatic or ischemic equivalent.

## 8. DISCUSSION

Appropriate use criteria define patient subgroups where the available medical evidence supplemented by expert opinion are combined to assess whether the net benefit or risks of a test or procedure make it reasonable to perform testing (in this document, echocardiography) in a particular clinical situation. The intent of these criteria is to guide the rational use of a procedure, namely avoidance of either under- or over-utilization, and thereby lead to improved outcomes, more optimal healthcare delivery, and justifiable healthcare expenditures.

This document is a revision and combination of the original AUC for transthoracic and transesophageal echocardiography (1) and stress echocardiography (2). The revision adds insight provided by interim clinical data and standards documents recently published in the literature and clarifies areas in which omissions or lack of clarity existed in the original criteria. Additionally, since publication of the original AUC, several studies have assessed the application of these criteria in clinical practice; results from these studies were incorporated into this revision and will be briefly summarized here.


### Implementation Studies

Application of the 2007 AUC for TTE has been evaluated at academic medical centers (22,24–26), in Veterans Affairs (VA) hospitals (27), and in community settings (28,29). Several common themes

deserve emphasis. First, the majority of clinical scenarios for which TTEs were ordered were captured by AUC indications (11% to 16% of TTEs were unclassified) (24,27). Second, across the implementation studies, there are remarkably similar rates of appropriate and inappropriate use of TTE. Among those TTEs with an indication addressed by the AUC (thus removing unclassifiable patients), the majority were rated as appropriate (87% to 91%) and the rate of inappropriate TTEs was consistently low (9% to 13%) (24–27). In 1 study of outpatient TTEs (29), the rate of appropriate TTEs was lower (74%), although this may be attributable to a higher proportion of unclassified studies in the outpatient setting, a pattern that has been observed by others (24,26). The presence of a greater proportion of unclassified TTEs in the outpatient setting might be expected given that many of the indications in the original AUC (1) specifically address symptoms or a “change in clinical status.”


The most common appropriate indications for TTE included initial evaluation of symptoms potentially caused by suspected cardiac etiology, prior testing concerning for heart disease, evaluation of valvular disease, and evaluation of a heart failure indication (24) and are repeated in this revision as Indications 1, 2, 34, and 70. Recommendations for expanding the AUC related to addressing 1) perioperative evaluation (Indications 13 and 14); 2) timing of follow up for valvular heart disease (Indications 38 to 41 and 43 to 49); 3) assessment for device therapy (Indications 76 to 83); and 4) use in some specialized care or “niche” programs (e.g., solid organ transplantation)

print & web 4C/FPO



**Figure 2** Stress echocardiography for detection of CAD/Risk assessment: Asymptomatic (without ischemic equivalent).

print & web 4C/FPO



**Figure 3** Stress echocardiography following prior treadmill ECG, coronary calcium scoring, or carotid intimal medial thickness test results.

(Indications 14, 84, and 85), and these scenarios were included in the current document. Finally, more indications reflecting outpatient clinical scenarios (e.g., no change in clinical status) were added.

Studies evaluating the application of AUC for TEE had similar results, with the vast majority of classifiable TEEs being ordered for appropriate indications (94% to 97%) and a smaller number not being classified by the AUC (6% to 9%) (30–32). The fact that the operator is more intimately involved in the decision to perform TEE may help to explain the higher appropriate use rate of TEE compared with TTE.

The most common indication for an initial TEE was to guide anticoagulation decisions in patients with atrial fibrillation or flutter (Indications 112 and 113) (30,31). Recommendations for revision focused on refinement of the indications for evaluation of cardiovascular source of embolus (Indications 109 to 111).

Fewer studies have focused on the clinical application of AUC for stress echocardiography (33,34). In 1 study, 19% of stress echocardiograms could not be classified by the AUC (33). Of the echocardiograms that were classified, 66% were for appropriate




Figure 4 Stress echocardiography following prior stress imaging or coronary angiogram test results.





Figure 5 Stress echocardiography for risk assessment—perioperative evaluation for noncardiac surgery without active cardiac conditions.



**Figure 6** Stress echocardiography for risk assessment—postrevascularization (PCI or CABG).

indications. The majority of unclassified studies were centered in 2 areas: perioperative risk assessment and risk assessment with prior test results. In another study, 88% (n=253) of stress echocardiograms were ordered for indications outlined in the AUC, whereas 12% (n=36) were ordered for indications not addressed by the AUC (34). Of the 253 studies for which the AUC document could be applied, 71% (n=180) studies were appropriate, 9% (n=23) were uncertain, and 20% (n=50) were inappropriate studies.

The results of the implementation studies demonstrate that the rate of inappropriate use of echocardiography is similar in various regions of the United States. In contrast, other studies of resource utilization have documented regional differences in utilization patterns (35). A recent study (36) suggests that a substantial amount of the observed geographic variability in use is attributable to corresponding regional differences in patient health, a conclusion supported by the AUC implementation data which, unlike claims data, inherently address clinical status. Further application of AUC may help to dissect the true variations in care delivery by supplementing claims data with clinical data; however, this warrants further study.

In summary, studies evaluating clinical application of AUC for echocardiography suggest that the majority of clinical scenarios could be classified by the criteria and that the majority of studies were ordered for appropriate indications. Further, the studies identified gaps in the AUC, likely due to both omissions in the initial criteria and subsequent advances in specialized care, which were of substantial utility in guiding the revision process. Although improved, we do not expect this AUC document to be all-inclusive of the wide breadth of all possible clinical scenarios. Although the results from the implementation studies indicate that the original AUC for echocardiography were successful, they also support the need for the current update and revision of the criteria.

#### Other Features of the Revision

In addition to incorporating the results from implementation studies, several other aspects of the revision deserve emphasis. First, the

revised document combines TTE, TEE, and stress echocardiography, whereas the initial TTE and TEE AUC (1) were published separately from the stress echocardiography AUC (2). The indication tables still focus on each modality separately, for example, TTE (or TEE as an adjunct if TTE nondiagnostic), TEE as an initial test, and stress echocardiography. The exception is the final table (Table 18, Indications 201 and 202), which covers contrast use and is applicable to all of the echocardiographic modalities. Second, a new table was created to cover indications related to patients with adult congenital heart disease, as this patient population is being encountered with greater frequency by adult cardiologists (Table 7, Indications 92 to 98) (37). It should be noted that, with the exception of some adults with ligated or occluded patent ductus arteriosus (covered in Indications 95 and 96), most congenital heart conditions have the potential for residual anatomic or physiologic abnormalities, so that, even for many asymptomatic and stable patients, an echocardiogram will be considered to guide therapeutic decision making rather than for routine surveillance. Third, existing tables were expanded to be more comprehensive in covering various clinical situations. Fourth, efforts were made to address clinical scenarios that have recently been addressed in revised or new practice guidelines, such as valvular heart disease (14), perioperative evaluation (16), and evaluation of thoracic aortic disease (38). The goal of relating indications to the available evidence base was a consistent feature during the revision process (see Online Appendix). If randomized trials or practice guidelines relevant to indications were not available, clinical scenarios addressed in expert consensus documents were identified whenever possible. Finally, indications were added to better address evolving therapeutic options such as CRT (Indications 76 to 78) or treatment/follow-up of pulmonary hypertension (Indications 15 to 18).

An important focus during the revision process was to harmonize the indications across noninvasive modalities, such that the wording of the indications is identical with other AUC criteria (3) whenever feasible. For echocardiography, harmonization with other documents was most relevant for the stress echocardiography portion. For instance, Table 13, which addresses the perioperative assessment for

noncardiac surgery, mirrors Table 4 in the RNI document (3). This should facilitate clinical application of the criteria and assist the process of future revisions and possibly the development of a multimodality imaging AUC document.

Stress echocardiography tests, like many imaging tests, may provide additional useful information beyond the primary purpose outlined by the indication. In addition, stress echocardiography does not use ionizing radiation. However, the AUC for stress echocardiography were not developed to quantify the incremental information or other test characteristics beyond addressing the diagnostic need inherent in an individual indication.

In ranking indications, panelists were asked to not consider comparisons to other imaging procedures while completing their rankings. Nevertheless, stress echocardiography and SPECT MPI have similar bodies of evidence to support their use. Therefore, it is not surprising that the overwhelming majority of final ratings of stress echocardiography and stress RNI were concordant for similar clinical indications. However, a small number of the final scores and rating categories reported in this document differ from those previously published for stress RNI (3). Specifically, 4 indications (Indications 127, 157, 171, and 172) were rated differently. It is noteworthy that of these 4 indications, 3 also appeared in the first stress echocardiography AUC (2), and all 3 indications were rated similarly in this revision, requiring consistency in ratings across the 2 technical panels composed of different individuals. The difference in the rating for Indication 127 may have been directly affected by publication of the DIAD study (39), which was not available at the time of the RNI ratings. Additionally, although the final rankings were different from the RNI ratings, Indications 127 and 171 demonstrated agreement within the current echocardiography technical panel. Therefore, the several indications with ratings that differed from RNI may reflect new literature that has become available since publication of the SPECT appropriateness criteria and differences in the composition of the 2 panels.

Readers should also note that the categorical summaries tend to accentuate differences that sometimes are slight. For example, small fluctuations in a median rating (e.g., 4 versus 3) will cause an indication to switch appropriateness categories (e.g., from uncertain to inappropriate). This phenomenon was relevant for Indication 157, which was rated as uncertain (median score 6) in this document, while the same indication in the RNI document (corresponding Indication 43) was rated appropriate (median score 7). The most likely reason for this is a simple variation in rating by the different panel members, whether because of composition, different levels of clinical experience, publication of additional literature, or different interpretations of data. The AUC Task Force has carefully examined the issue of panel membership and made every effort to ensure similar composition for each panel. The RAND process has documented that the interpretation of the literature by different sets of experts can yield slightly different final ratings (6).

As described in the Methods section, within each main disease category, a standardized approach was used in order to capture the majority of clinical scenarios without making the list of indications excessive. The approach was to create 5 broad clinical scenarios: 1) for initial diagnosis; 2) to guide therapy or management, regardless of symptom status; 3) to evaluate a change in clinical status or cardiac exam; 4) for early follow-up without change in clinical status; and 5) for late follow-up without change in clinical status. It should be noted that many cardiovascular conditions have the potential for residual anatomic or physiologic abnormalities, so that the timing and follow-up use of echocardiographic imaging depends on the patient's clinical status and the magnitude of or risk for residual abnormalities.

Thus, routine surveillance indications for echocardiograms should not apply in those situations in which there has been a change in status or where an echocardiogram is being considered to guide therapeutic decision making. For asymptomatic or stable patients with known or suspected residual anatomic or physiologic abnormalities, the timing of the follow-up for considering changes in therapy in patients should be determined by individual patient factors, and not by the suggested intervals for routine surveillance studies.

Overall, indications focusing on initial diagnosis, guidance of therapy, or evaluation of a change in clinical status were viewed favorably by the rating panel. Uncertain or inappropriate ratings were more likely given to early rather than late follow-up, especially for those indications when the optimal interval of follow-up for asymptomatic patients is uncertain. Whenever possible, indications for timing of follow-up attempted to follow practice guidelines (14), although for many indications, the most appropriate follow-up interval for asymptomatic patients is not well established. For this reason, as well as for clinical expediency, the follow-up interval selected is not meant to be rigid but rather to represent an approximate time interval.

Although the overall approach was broad and inclusive, certain specific clinical scenarios warranted focused indications based on results from the previously mentioned implementation studies. Examples include Indications 71 and 72, which differentiate the re-evaluation of decompensated heart failure when there is no clear precipitating change in medication or diet versus when there is a clear precipitating factor. In the setting of an obvious change in diet or medication, a trial of appropriate medical therapy and monitoring for clinical improvement may be justified prior to ordering a repeat imaging test for assessment of cardiac function (25). As such, Indication 72 (clear precipitating change in medication or diet) was rated as uncertain, and Indication 71 was rated as appropriate. Another focused clinical situation is reflected in Indication 76, "Initial evaluation or re-evaluation after revascularization and/or optimal medical therapy to determine candidacy for device therapy and/or to determine optimal choice of device." As per the results of an implementation study (24), this clinical scenario was not well captured in the initial AUC document. However, re-evaluation of LV ejection fraction after revascularization or after a period of medical therapy to determine device candidacy represents a standard of care (40) and is a common indication for a TTE. This is now represented by Indication 76, which was rated as appropriate.

Other specific areas identified by implementation studies as common scenarios and now included are bradycardia (Indication 6) and a new subcategory within TTE for the evaluation of syncope (Indications 7 to 9). Additionally, the sections on valvular heart disease (both resting TTE/TEE and stress echocardiography for hemodynamics) have been expanded in an effort to address a greater number of clinical scenarios, and closely follow recent guideline recommendations (14).

Despite these extensive revisions and additions, all potential clinical scenarios were not covered by the revised AUC for echocardiography. Additionally, certain recommendations from implementation studies were considered to represent rare conditions or specialized practices and were therefore not included in the revised document. If certain clinical situations that are not currently covered are found to be more frequent than anticipated, they will be incorporated into future revisions. This emphasizes the iterative nature of this process.

Furthermore, there are several general categories that were purposefully not addressed. For example, intraoperative use of TEE for cardiac surgery was felt to be beyond the scope of this document.

More highly specialized echocardiographic techniques, such as 3-dimensional echocardiography or epicardial imaging, are not addressed in this document. Additionally, as stated in the first paragraph of the Assumptions section, the AUC for TTE, TEE, and stress echocardiography are for adult patients. Indications for pediatric echocardiograms were not covered.

### New Assumptions and Definition

In addition to adding new clinical indications and clarifying existing indications from the original TTE/TEE AUC (1) and stress echocardiography AUC (2), the writing group also revised and added specific assumptions and definitions. Several general assumptions were added. First, the assumption that cost should be implicitly considered in determining appropriate use of an echocardiogram was added. Second, a new assumption addresses the category of uncertain indications and clarifies that such a rating should not be considered grounds for withholding reimbursement. Third, a new assumption indicates that appropriateness ratings reflect whether a specific test is appropriate for a given patient, not whether it is preferred over another modality (e.g., RNI, CT). Thus, the AUC should not be used to provide clinical support for administrative policies regarding test preferences. Finally, an assumption clarifies that routine or surveillance echocardiograms represent a "periodic" evaluation after a certain period of time has elapsed, and are not being ordered because of any other clinical factors. Other more specific assumptions were also added. These include consideration of prosthetic and native valves together (unless otherwise specified) and that use of Doppler for hemodynamics includes assessment of both right and left heart hemodynamics. Furthermore, it is assumed that if a perioperative patient has symptoms or signs of cardiovascular disease, the study should be classified under a symptomatic indication (e.g., Indication 1), as opposed to an indication in the perioperative category.

Similar to the RNI AUC (3), the writing group revised the definition of "chest pain syndrome" and adopted the term "ischemic equivalent," which encompasses chest pain syndromes as well as other symptoms and signs that the clinician believes may be attributable to CAD. The writing group also adopted the use of global risk assessment when assessing risk in asymptomatic patients (41). This revision was supported by the writing group, technical panel, and external reviewers and is in harmony with the most recent AUC for Cardiac CT (4).

### Limitations

The ratings of the indications as appropriate, uncertain, or inappropriate are reflective of the body of knowledge at the time the rating process occurred. It is likely and expected that as science progresses and new evidence-based guidelines are published, certain indications that are given 1 rating may subsequently be determined to have a different appropriateness rating in the future. Although this necessarily reflects the evolving nature of medical science, it may also introduce apparent discrepancies between appropriateness of similar indications for different modalities evaluated at different time points. The current evidence base and practice guidelines were used to develop the indications whenever available, although for certain indications the literature was limited and clinical expertise played a larger role. This is consistent with the standard methodology and principles of evidence-based medicine as endorsed by the Physician Consortium for Performance Improvement (42). Additionally, as mentioned in the previous text, certain clinical scenarios were intentionally not covered by the indications. When future implementation studies evaluat-

ing this revised AUC for echocardiography are conducted, it may become apparent that frequent situations were not covered. As was the case for this current revision, results and recommendations from implementation studies will help shape future modifications to the AUC.

### Use of AUC to Improve Care

The AUC in this report provide an estimate of whether it is reasonable to use echocardiography for a particular clinical scenario, specifically for 1 of the 202 indications listed in this document. These criteria are expected to be useful for clinicians, healthcare facilities, and third-party payers engaged in the delivery of cardiovascular imaging. The AUC is expected to be valuable across a broad range of situations, including guiding care of individual patients, educating caregivers, and informing policy decisions regarding cardiovascular imaging.

AUC represent the first component of the chain of quality domains for cardiovascular imaging (43). After ensuring proper test selection, the achievement of quality in imaging includes adherence to best practices in image acquisition, image interpretation and results communication, as well as incorporation of findings into clinical care. All components are important for optimal patient care, although the development of AUC and their ranking by the technical panel is intended to address only the first quality domain, and assumes no barriers to other quality standards are being met.

Although these criteria are intended to provide guidance for care decisions, they cannot serve as substitutes for sound clinical judgment and practice experience. The writing group recognizes that patients encountered in clinical practice may not be represented in these AUC or may have extenuating features when compared with the clinical scenarios presented. Additionally, uncertain indications often require individual physician judgment and an in-depth understanding of the patient to better determine the usefulness of a test for a particular scenario. As such, the ranking of an indication as uncertain (4 to 6) should not be viewed as limiting the use of echocardiography for such patients. It should be emphasized that the technical panel was instructed that the "uncertain" designation was still designed to be considered as a "reimbursable" category.

These ratings reflect the critical medical literature as well as expert consensus and are intended to evaluate the appropriate use of specific patient scenarios to determine overall patterns of care regarding echocardiography. In situations where there is substantial variation between the appropriate use rating and what the clinician believes is the best recommendation for the patient, further considerations or actions, such as a second opinion, may be appropriate. Moreover, it is neither anticipated nor desirable that all physicians or facilities will have 100% of their echocardiograms deemed appropriate. However, it is desirable, though not realistic, that 0% be inappropriate. Related to the overall patterns of care, if the national average of appropriate and uncertain ratings is 80%, for example, and a physician or facility has a 40% rate of inappropriate procedures, further examination of the patterns of care may be warranted and helpful. The use of AUC to guide clinical decision making and its impact on patient outcomes and healthcare quality/efficiency needs to be studied rigorously. AUC are also useful as educational tools for both echocardiography providers and referring physicians. The recently announced and soon to be implemented incorporation of AUC into echocardiography laboratory accreditation requirements will encourage their use (44). However, the greatest opportunity to optimize the use of echocardiography is in improving individual patient decision making. The successful application of AUC into clinical practice represents an important area of ongoing quality improvement.

**APPENDIX A: ADDITIONAL ECHOCARDIOGRAPHY DEFINITIONS**

1. Angina

- **Typical Angina (Definite):** Defined as 1) substernal chest pain or discomfort that is 2) provoked by exertion or emotional stress and 3) relieved by rest and/or nitroglycerin (45).
- **Atypical Angina (Probable):** Chest pain or discomfort that **lacks 1** of the characteristics of definite or typical angina.
- **Nonanginal Chest Pain:** Chest pain or discomfort that **meets 1 or none** of the typical angina characteristics.

2. Acute Coronary Syndrome (ACS)

As defined by the ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: patients with an ACS include those whose clinical presentations cover the following range of diagnoses: unstable angina, myocardial infarction without ST-segment elevation (NSTEMI), and myocardial infarction with ST-segment elevation (STEMI) (46).

3. Evaluating Perioperative Risk for Noncardiac Surgery


**Method for Determining Perioperative Risk.** See Figure A1, "Stepwise Approach to Perioperative Cardiac Assessment," from

the ACCF/AHA guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery (16). Based on the algorithm, once it is determined that the patient does not require urgent surgery, the clinician should determine the patient's active cardiac conditions (see Table A1) and/or perioperative risk predictors (see Table A2). If any active cardiac conditions and/or major risk predictors are present, Figure A1 suggests consideration of coronary angiography and postponing or canceling noncardiac surgery. Once perioperative risk predictors are assessed based on the algorithm, then the surgical risk and patient's functional status should be used to establish the need for noninvasive testing.

4. Thrombolysis In Myocardial Infarction (TIMI) Risk Scores

The TIMI risk score (48) is a simple tool composed of 7 (1-point) risk indicators rated on presentation. The composite end points (all-cause mortality, new or recurrent MI, or severe recurrent ischemia prompting urgent revascularization within 14 days) increase as the TIMI risk score increases. The model remained a significant predictor of events and test sensitivity and was relatively unaffected/uncompromised by missing information, such as knowledge of previously documented coronary stenosis of  $\geq 50\%$ . The model's predictive ability remained intact with a cutoff of 65 years of age.

The TIMI risk score is determined by the sum of the presence of 7 variables at admission; 1 point is given for each of the following



**Figure A1** Stepwise approach to perioperative cardiac assessment.

Cardiac evaluation and care algorithm for noncardiac surgery based on active clinical conditions, known cardiovascular disease, or cardiac risk factors for patients  $\geq 50$  years of age. HR indicates heart rate; LOE, level of evidence; and MET, metabolic equivalent. Modified from (16).

**Table A1** Active cardiac conditions for which the patient should undergo evaluation and treatment before noncardiac surgery (class I, level of evidence: B)

Condition	Examples
Unstable coronary syndromes	Unstable or severe angina* (CCS class III or IV) <sup>†</sup> Recent MI <sup>‡</sup>
Decompensated HF (NYHA functional class IV; worsening or new-onset HF)	
Significant arrhythmias	High-grade atrioventricular block Mobitz II atrioventricular block Third-degree atrioventricular heart block Symptomatic ventricular arrhythmias Supraventricular arrhythmias (including atrial fibrillation) with uncontrolled ventricular rate (HR >100 bpm at rest) Symptomatic bradycardia Newly recognized ventricular tachycardia
Severe valvular disease	Severe aortic stenosis (mean pressure gradient >40 mm Hg, aortic valve area <1.0 cm <sup>2</sup> , or symptomatic) Symptomatic mitral stenosis (progressive dyspnea on exertion, extertional presyncope, or HF)

CCS indicates Canadian Cardiovascular Society; HF, heart failure; HR, heart rate; MI, myocardial infarction; and NYHA, New York Heart Association.

\*According to Campeau (47).

<sup>†</sup>May include “stable” angina in patients who are unusually sedentary.

<sup>‡</sup>The American College of Cardiology National Database Library defines recent MI as >7 days but ≤1 month (within 30 days). Reprinted from Fleisher et al. (16).

variables: age ≥65 years, at least 3 risk factors for CAD, prior coronary stenosis of ≥50%, ST-segment deviation on ECG presentation, at least 2 anginal events in prior 24 hours, use of aspirin in prior 7 days, and elevated serum cardiac biomarkers.

Low-Risk TIMI Score: TIMI score <2

High-Risk TIMI Score: TIMI score ≥2

## 5. ECG—Uninterpretable

Refers to ECGs with resting ST-segment depression (≥0.10 mV), complete LBBB, pre-excitation (Wolff-Parkinson-White Syndrome), or paced rhythm.

## 6. Coronary Angiography

The term *coronary angiography* refers to invasive cardiac catheterization or to established noninvasive methods of imaging the coronary arteries, such as coronary CT angiography.

**Table A2** Perioperative clinical risk factors\*

• History of ischemic heart disease
• History of compensated or prior heart failure
• History of cerebrovascular disease
• Diabetes mellitus (requiring insulin)
• Renal insufficiency (creatinine >2.0)

\*As defined by the 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery (16). Note that these are not standard coronary artery disease risk factors.

## APPENDIX B: ADDITIONAL METHODS

See the Methods section of the report for a description of panel selection, indication development, scope of indications, and rating process.

### Relationships With Industry and Other Entities

A list of all individuals participating in the development and review of this document and their institutional and/or organizational affiliations is presented in [Appendix C](#). The American College of Cardiology Foundation and its partnering organizations rigorously avoid any actual, perceived, or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the technical panel. Specifically, all panelists are asked to provide disclosure statements of all relationships that might be perceived as real or potential conflicts of interest. These statements were reviewed by the Appropriate Use Criteria Task Force, discussed with all members of the technical panel at the face-to-face meeting, and updated and reviewed as necessary. A table of disclosures by the technical panel and oversight working group member can be found in [Appendix D](#). In addition, to ensure complete transparency, complete disclosure information—including relationships not pertinent to this document—is available online as a document supplement.

### Literature Review

The technical panel members were asked to refer to the relevant literature provided for each indication table when completing their ratings (see Online Appendix).

## APPENDIX C: ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011

### Appropriate Use Criteria for Echocardiography Participants

#### Echocardiography Writing Group

Pamela S. Douglas, MD, MACC, FAHA, FASE—Chair, Appropriate Use Criteria for Echocardiography, Past President, American College of Cardiology Foundation; Past President American Society of Echocardiography; and Ursula Geller Professor of Research in Cardiovascular Diseases, Duke University Medical Center, Durham, NC

Mario J. Garcia, MD, FACC, FACP—Professor of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY

**Appendix C** ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography Writing Group, Technical Panel, Indication Reviewers, and Task Force—Relationships With Industry and Other Entities (in alphabetical order within each group)

Participant	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
<b>Echocardiography Appropriate Use Criteria Writing Group</b>						
Pamela S. Douglas	None	None	None	None	None	None
Mario J. Garcia	None	None	None	None	None	None
David E. Haines	None	None	None	None	None	None
Wyman W. Lai	None	None	None	None	None	None
Warren J. Manning	• Lantheus Medical Imaging	None	None	• Philips Medical Systems	None	None
Ayan R. Patel	None	None	None	None	None	None
Michael H. Picard	None	None	None	• Edwards Lifesciences	None	None
Donna M. Polk	None	None	None	None	None	None
Michael Ragosta	None	None	None	None	None	None
R. Parker Ward	None	None	None	None	None	None
Rory B. Weiner	None	None	None	None	None	None
<b>Echocardiography Appropriate Use Criteria Technical Panel</b>						
Steven R. Bailey	None	None	None	None	None	None
Rory B. Weiner	None	None	None	None	None	None
Peter Alagona, Jr	None	None	None	None	None	None
Jeffrey L. Anderson	None	None	None	• Toshiba	None	None
Jeanne M. DeCara	None	None	None	None	None	None
Rowena J. Dolor	None	None	None	None	None	None
Reza Fazel	None	None	None	None	None	None
John A. Gillespie	None	None	None	None	None	None
Paul A. Heidenreich	None	None	None	None	None	None
Luci K. Leykum	None	None	None	None	None	None
Joseph E. Marine	None	None	None	None	None	None
Gregory J. Mishkel	None	None	None	None	None	None
Patricia A. Pellikka	None	None	None	None	None	None
Gilbert L. Raff	None	None	None	None	None	None
Krishnaswami Vijayaraghavan	None	None	None	None	None	None
Neil J. Weissman	None	None	None	None	None	None
Katherine C. Wu	None	None	None	None	None	None
<b>Echocardiography Appropriate Use Criteria Indication Reviewers</b>						
Drew Baldwin	None	None	None	None	• Veterans Affairs	None
Thomas Behrenbeck	None	None	None	None	None	None
Michael Blaivas	None	None	None	None	None	None
Jeanne M. DeCara	None	None	None	None	None	None
Peter L. Duffy	None	None	None	None	None	None
Kirsten E. Fleischmann	None	None	None	None	None	None
Shawn A. Gregory	None	None	None	None	None	None
Frederick G. Kushner	None	None	None	None	None	None
John Lesser	• Vital Images	• Siemens Medical Systems	None	None	None	None
Alexander B. Levitov	• Lantheus Medical Imaging	None	None	None	None	None
Kapildeo Lotun	None	None	None	None	None	None
John V. Nixon	None	None	None	None	None	None
David T. Porembka	None	None	None	None	None	None
Brian D. Powell	None	None	None	None	None	None
Subha Raman	None	None	None	None	None	None
Gregory S. Thomas	None	None	None	None	None	None
James D. Thomas	None	None	None	None	None	None

(Continued)

## Appendix C (Continued)

Participant	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Aseem Vashist	None	None	None	None	None	None
Mary N. Walsh	None	None	None	None	None	None
Carole A. Warnes	None	None	None	None	None	None
Joseph N. Wight, Jr	None	None	None	None	None	None
Katherine C. Wu	None	None	None	None	None	None
<b>Echocardiography Appropriate Use Criteria Task Force</b>						
Michael J. Wolk	None	None	None	None	None	None
Steven R. Bailey	None	None	None	None	None	None
Pamela S. Douglas	None	None	None	None	None	None
Robert C. Hendel	None	None	None	None	None	None
Christopher M. Kramer	None	None	None	None	None	None
James K. Min	None	• General Electric Healthcare	None	None	None	None
Manesh R. Patel	• Genzyme	None	None	None	None	None
Leslee Shaw	None	None	None	None	None	None
Raymond F. Stainback	None	None	None	None	None	None
Joseph M. Allen	None	None	None	None	None	None

This table represents the relevant relationships with industry and other entities that were disclosed by participants at the time of participation. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of \$10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Participation does not imply endorsement of this document.

\*Significant relationship.

David E. Haines, MD, FACC, FHRS—Professor of Cardiovascular Medicine, Oakland University, William Beaumont School of Medicine, Chairman, Department of Cardiovascular Medicine, Beaumont Hospitals, Royal Oak, MI

Wyman W. Lai, MD, MPH, FACC, FASE—Morgan Stanley Children's Hospital of NY, Pediatric Cardiology, Director, Noninvasive Cardiac Imaging Laboratory, New York, NY

Warren J. Manning, MD, FACC—Professor of Medicine and Radiology, Harvard Medical School, Beth Israel Deaconess Medical Center, Cardiovascular Division, Boston, MA

Ayan R. Patel, MD, FACC—Director, Cardiovascular Imaging & Hemodynamic Laboratory and Physician, Heart Failure & Cardiac Transplant Center, Tufts Medical Center; Associate Professor of Medicine, Tufts University School of Medicine, Boston, MA

Michael H. Picard, MD, FACC, FASE, FAHA—Director, Echocardiography, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston, MA

Donna M. Polk, MD, MPH, FACC, FASE, FASNC—Director, Preventative Cardiology, Hartford Hospital, Hartford, CT

Michael Ragosta, MD, FACC, FSCAI—Professor of Medicine/ Cardiology, Director, Cardiac Catheterization Laboratories, Department of Medicine, Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA

R. Parker Ward, MD, FACC, FASE, FASNC—Associate Professor of Medicine, Director of Cardiovascular Fellowship Program, University of Chicago Medical Center, Chicago, IL

Rory B. Weiner, MD—Clinical and Research Fellow, Harvard Medical School, Massachusetts General Hospital, Cardiology Division, Boston, MA

## Echocardiography Technical Panel

Steven R. Bailey, MD, FACC, FSCAI, FAHA—Moderator of the Technical Panel, Chair, Division of Cardiology, Professor of Medicine and Radiology, Janey Briscoe Distinguished Chair, University of Texas Health Sciences Center, San Antonio, TX

Rory B. Weiner, MD—Writing Group Liaison Appropriate Use Criteria for Echocardiography Technical Panel, Clinical and Research Fellow, Harvard Medical School, Massachusetts General Hospital, Cardiology Division, Boston, MA

Peter Alagona, Jr, MD, FACC—Program Director General Cardiology, Penn State Heart and Vascular Institute, Hershey, PA

Jeffrey L. Anderson, MD, FACC, FAHA, MACP—Professor of Medicine, University of Utah, Associate Chief of Cardiology, Intermountain Medical Center, Salt Lake City, UT

Jeanne M. DeCara, MD, FACC, FASE—Associate Professor of Medicine, University of Chicago Medical Center, Chicago, IL

Rowena J. Dolor, MD, MHS—Assistant Professor, General Internal Medicine, Duke University Medical Center, Durham, NC

Reza Fazel, MD, FACC—Assistant Professor of Medicine, Emory University, Atlanta, GA

John A. Gillespie, MD, FACC—Clinical Assistant Professor of Family Medicine, University of Buffalo, Buffalo, NY

Paul A. Heidenreich, MD, FACC—Assistant Professor of Medicine, Stanford, VA Palo Alto Health Care System, Palo Alto, CA

Luci K. Leykum, MD, MBA, MSc—Associate Professor of Medicine, South Texas Veterans Health Care System/UT Health Science Center San Antonio, San Antonio, TX

Joseph E. Marine, MD, FACC, FHRS—Director of Electrophysiology, Johns Hopkins Bayview Medical Center;

Associate Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

Gregory J. Mishkel, MD, FACC, FSCAI, FRCPC—Co-Director, Cardiac Cath Lab, St. John's Hospital, Director Interventional Cardiology, St. Mary's Hospital, Prairie Cardiovascular Consultants, Springfield and Decatur, IL

Patricia A. Pellikka, MD, FACC, FAHA, FACP, FASE—Professor of Medicine, Mayo Clinic College of Medicine, Co-Director, Echocardiography Laboratory, Mayo Clinic, Rochester, MN

Gilbert L. Raff, MD, FACC, FSCCT—Director, Cardiac CT/MRI, William Beaumont Hospitals, Royal Oak, MI

Krishnaswami Vijayaraghavan, MD, FACC, FCCP—Medical Director, CV Research and Education, Scottsdale Healthcare, Scottsdale, AZ

Neil J. Weissman, MD, FACC, FAHA—President, MedStar Health Research Institute, Professor of Medicine, Georgetown University School of Medicine, Washington, DC

Katherine C. Wu, MD—Associate Professor of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD

#### External Reviewers of the Appropriate Use Criteria Indications

Drew Baldwin, MD—Assistant Professor of Clinical Medicine, Tulane University Heart and Vascular Institute, New Orleans, LA

Thomas Behrenbeck, MD, PhD, FCCP—Associate Professor of Medicine, Mayo Clinic, Rochester, MN

Michael Blaivas, MD, FACEP—Professor of Emergency Medicine, Northside Hospital Forsyth, Atlanta, GA

Robert O. Bonow, MD, MACC—Goldberg Distinguished Professor, Chief, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL

Jeanne M. DeCara, MD, FACC, FASE—Associate Professor of Medicine, University of Chicago Medical Center, Chicago, IL

Peter L. Duffy, MD, FACC—Cardiologist, Partner, Pinehurst Cardiology Consultants, Pinehurst, NC

Kirsten E. Fleischmann, MD, MPH, FACC—Associate Professor of Medicine, University of California San Francisco School of Medicine, Division of Cardiology, San Francisco, CA

Shawn A. Gregory, MD—Cardiologist, Massachusetts General Hospital, Boston, MA

Scott D. Jerome, DO, FACC, FASNC, FSCCT—Assistant Professor of Medicine, University of Maryland School of Medicine, Director of Ambulatory Outreach Cardiology, Baltimore, MD

Frederick G. Kushner, MD, FACC—Clinical Professor, Tulane University Medical Center, Medical Director, Heart Clinic of Louisiana, Marrero, LA

John Lesser, MD, FACC—Director of Cardiovascular CT and MRI, Minneapolis Heart Institute, Minneapolis, MN

Alexander B. Levitov, MD—Professor, Eastern Virginia Medical School, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Norfolk, VA

Kapildeo Lotun, MD—Assistant Professor of Medicine, Chief, Section of Vascular Medicine, Interventional Cardiology, Virginia Commonwealth University, Division of Cardiology, Richmond, VA

Jennifer H. Mieres, MD, FACC—Associate Professor of Medicine, Hofstra NorthShore-LIJ School of Medicine, Department of Cardiology, Manhasset, NY

Todd D. Miller, MD, FACC—Professor of Medicine, Cardiovascular Diseases, Mayo Graduate School of Medicine, Mayo Clinic, Rochester, MN

John V. Nixon, MD, FACC, FAHA—Professor of Medicine, Medical College of Virginia, Virginia Commonwealth University, Director, Echocardiography Laboratories and Heart Station, Richmond, VA

David T. Porembka, MD—Director of Perioperative Echocardiography, Professor of Anesthesia, Surgery, and Internal Medicine, University of Cincinnati Academic Center, Department of Anesthesiology, Cincinnati, OH

Brian D. Powell, MD, FACC—Assistant Professor of Medicine, Mayo Clinic, Rochester, MN

Subha Raman, MD—Associate Professor of Medicine, Ohio State University, Columbus, OH

Gregory S. Thomas, MD, MPH, FACC—Director, Nuclear Cardiology, Co-Director, Lipid Clinic, Mission Internal Medical Group, Clinical Associate Professor of Medicine, Director of Nuclear Cardiology Training, University of California, Irvine School of Medicine, Dana Point, CA

James D. Thomas, MD, FACC—Director of Cardiovascular Imaging, Cleveland Clinic Foundation, Cleveland, OH

Aseem Vashist, MD—Cardiologist, Hartford Cardiology Group, Hartford, CT

Mary N. Walsh, MD, FACC—Medical Director, Heart Failure and Cardiac Transplantation, St. Vincent Hospital, Clinical Associate Professor, Indiana University School of Medicine, Indianapolis, IN

Carole A. Warnes, MD, FACC—Professor of Medicine, Mayo Clinic, Rochester, MN

Joseph N. Wight, Jr, MD, FACC—Clinical Assistant Professor of Medicine, University of Vermont School of Medicine, Director of Heart Failure, Maine Medical Center, Director of Echocardiography, Maine Cardiology Associates, South Portland, ME

Kim A. Williams, MD, FACC, FAHA, FASNC—Dorothy Susan Timmis Professor and Chair, Division of Cardiology, Professor of Medicine, Wayne State University School of Medicine, Harper University Hospital, Detroit, MI

Katherine C. Wu, MD—Associate Professor of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD

#### Appropriate Use Criteria Task Force

Michael J. Wolk, MD, MACC—Chair, Task Force, Past President, American College of Cardiology Foundation and Clinical Professor of Medicine, Weill-Cornell Medical School, New York, NY

Steven R. Bailey, MD, FACC, FSCAI, FAHA—Chair, Division of Cardiology, Professor of Medicine and Radiology, Janey Briscoe Distinguished Chair, University of Texas Health Sciences Center, San Antonio, TX

Pamela S. Douglas, MD, MACC, FAHA, FASE—Past President, American College of Cardiology Foundation; Past President American Society of Echocardiography; and Ursula Geller Professor of Research in Cardiovascular Diseases, Duke University Medical Center, Durham, NC

Robert C. Hendel, MD, FACC, FAHA, FASNC—Chair, Appropriate Use Criteria for Radionuclide Imaging Writing Group—Director of Cardiac Imaging and Outpatient Services, Division of Cardiology, Miami University School of Medicine, Miami, FL

Christopher M. Kramer, MD, FACC, FAHA—Professor of Medicine and Radiology and Director, Cardiovascular Imaging Center, University of Virginia Health System, Charlottesville, VA

James K. Min, MD, FACC—Assistant Professor of Medicine, Division of Cardiology, Assistant Professor of Radiology, Weill

Cornell Medical College, New York Presbyterian Hospital, New York, NY

Manesh R. Patel, MD, FACC—Assistant Professor of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC

Leslee Shaw, PhD, FACC, FASNC—Professor of Medicine, Emory University School of Medicine, Atlanta, GA

Raymond F. Stainback, MD, FACC, FASE—Medical Director of Noninvasive Cardiac Imaging, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas; Clinical Associate Professor of Medicine, Baylor College of Medicine; President-Elect, Intersocietal Commission for the Accreditation of Echocardiography Laboratories (ICAEL); Hall-Garcia Cardiology Associates, Houston, TX

Joseph M. Allen, MA—Director, TRIP (Translating Research into Practice), American College of Cardiology Foundation, Washington, DC

**APPENDIX D: ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 APPROPRIATE USE CRITERIA FOR ECHOCARDIOGRAPHY WRITING GROUP, TECHNICAL PANEL, INDICATION REVIEWERS, AND TASK FORCE—RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (IN ALPHABETICAL ORDER WITHIN EACH GROUP)**

**Staff**

**American College of Cardiology Foundation.** John C. Lewin, MD, Chief Executive Officer Joseph M. Allen, MA, Director, TRIP (Translating Research Into Practice)

Starr Webb, MPH, Senior Specialist, Appropriate Use Criteria  
Jenissa Haidari, MPH, Senior Specialist, Appropriate Use Criteria  
Lea Binder, MA, Specialist, Appropriate Use Criteria  
Elin A. Barrett, MPS, Senior Specialist, Science and Clinical Policy (17)

**Appendix D ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography Writing Group, Technical Panel, Indication Reviewers, and Task Force—Relationships With Industry and Other Entities (in alphabetical order within each group)**

Participant	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
<b>Echocardiography Appropriate Use Criteria Writing Group</b>						
Pamela S. Douglas	None	None	None	None	None	None
Mario J. Garcia	None	None	None	None	None	None
David E. Haines	None	None	None	None	None	None
Wyman W. Lai	None	None	None	None	None	None
Warren J. Manning	•Lantheus Medical Imaging	None	None	•Philips Medical Systems*	None	None
Ayan R. Patel	None	None	None	None	None	None
Michael H. Picard	None	None	None	•Edwards Lifesciences	None	None
Donna M. Polk	None	None	None	None	None	None
Michael Ragosta	None	None	None	None	None	None
R. Parker Ward	None	None	None	None	None	None
Rory B. Weiner	None	None	None	None	None	None
<b>Echocardiography Appropriate Use Criteria Technical Panel</b>						
Steven R. Bailey	None	None	None	None	None	None
Rory B. Weiner	None	None	None	None	None	None
Peter Alagona, Jr	None	None	None	None	None	None
Jeffrey L. Anderson	None	None	None	•Toshiba	None	None
Jeanne M. DeCara	None	None	None	None	None	None
Rowena J. Dolor	None	None	None	None	None	None
Reza Fazel	None	None	None	None	None	None
John A. Gillespie	None	None	None	None	None	None
Paul A. Heidenreich	None	None	None	None	None	None
Luci K. Leykum	None	None	None	None	None	None
Joseph E. Marine	None	None	None	None	None	None
Gregory J. Mishkel	None	None	None	None	None	None
Patricia A. Pellikka	None	None	None	None	None	None
Gilbert L. Raff	None	None	None	None	None	None
Krishnaswami Vijayaraghavan	None	None	None	None	None	None
Neil J. Weissman	None	None	None	None	None	None
Katherine C. Wu	None	None	None	None	None	None

(Continued)

Appendix D (Continued)

Participant	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Echocardiography Appropriate Use Criteria Indication Reviewers						
Drew Baldwin	None	None	None	None	●Veterans Affairs*	None
Thomas Behrenbeck	None	None	None	None	None	None
Michael Blaivas	None	None	None	None	None	None
Robert O. Bonow	None	None	None	None	None	None
Jeanne M. DeCara	None	None	None	None	None	None
Peter L. Duffy	None	None	None	None	None	None
Kirsten E. Fleischmann	None	None	None	None	None	None
Shawn A. Gregory	None	None	None	None	None	None
Scott D. Jerome	None	None	None	None	None	None
Frederick G. Kushner	None	None	None	None	None	None
John Lesser	●Vital Images	●Siemens Medical Systems	None	None	None	None
Alexander B. Levitov	●Lantheus Medical Imaging	None	None	None	None	None
Kapildeo Lotun	None	None	None	None	None	None
Jennifer H. Mieres	None	None	None	None	None	None
Todd D. Miller	None	None	None	None	None	None
John V. Nixon	None	None	None	None	None	None
David T. Porembka	None	None	None	None	None	None
Brian D. Powell	None	None	None	None	None	None
Subha Raman	None	None	None	None	None	None
Gregory S. Thomas	None	None	None	None	None	None
James D. Thomas	None	None	None	None	None	None
Aseem Vashist	None	None	None	None	None	None
Mary N. Walsh	None	None	None	None	None	None
Carole A. Warnes	None	None	None	None	None	None
Joseph N. Wight, Jr	None	None	None	None	None	None
Kim A. Williams	None	None	None	None	None	None
Katherine C. Wu	None	None	None	None	None	None
Echocardiography Appropriate Use Criteria Task Force						
Michael J. Wolk	None	None	None	None	None	None
Steven R. Bailey	None	None	None	None	None	None
Pamela S. Douglas	None	None	None	None	None	None
Robert C. Hendel	None	None	None	None	None	None
Christopher M. Kramer	None	None	None	None	None	None
James K. Min	None	●General Electric Healthcare	None	None	None	None
Manesh R. Patel	●Genzyme	None	None	None	None	None
Leslee Shaw	None	None	None	None	None	None
Raymond F. Stainback	None	None	None	None	None	None
Joseph M. Allen	None	None	None	None	None	None

This table represents the relevant relationships with industry and other entities that were disclosed by participants at the time of participation. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of \$10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Participation does not imply endorsement of this document.

\*Significant relationship.

**SUPPLEMENTARY DATA**

For supplementary data, please see the online version of this article.

**REFERENCES**

- Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. *J Am Coll Cardiol* 2007;50:187-204.
- Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 appropriateness criteria for stress echocardiography: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, American Society of Echocardiography, American College of Emergency Physicians, American Heart Association, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance endorsed by the Heart Rhythm Society and the Society of Critical Care Medicine. *J Am Coll Cardiol* 2008;51:1127-47.
- Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. *J Am Coll Cardiol* 2009;53:2201-29.
- Taylor AJ, Cequeira M, Hodgson J, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. *J Am Coll Cardiol* 2010;56:1864-94.
- Patel MR, Spertus JA, Brindis RG, et al. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. *J Am Coll Cardiol* 2005;46:1606-13.
- Fitch K, Bernstein SJ, Aguilar MD. The RAND/UCLA Appropriateness Method User's Manual. Arlington, Va: RAND; 2001.
- Quinones MA, Otto CM, Stoddard M, et al. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. *J Am Soc Echocardiogr* 2002;15:167-84.
- Thomas JD, Adams DB, Devries S, et al. Guidelines and recommendations for digital echocardiography. *J Am Soc Echocardiogr* 2005;18:287-97.
- Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr* 2005;18:1440-63.
- Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. *J Am Soc Echocardiogr* 2007;20:1021-41.
- Mulvagh SL, Rakowski H, Vannan MA, et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. *J Am Soc Echocardiogr* 2008;21:1179-201. quiz 1281.
- Ryan T, Armstrong WF, Khandheria BK. Task force 4: training in echocardiography endorsed by the American Society of Echocardiography. *J Am Coll Cardiol* 2008;51:361-7.
- Quinones MA, Douglas PS, Foster E, et al. ACC/AHA clinical competence statement on echocardiography: a report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence. *J Am Coll Cardiol* 2003;41:687-708.
- Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). *J Am Coll Cardiol* 2008;52:e1-142.
- Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. *J Am Soc Echocardiogr* 2009;22:975-1014. quiz 1082-4.
- Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2009;54:e13-118.
- Plotkin JS, Benitez RM, Kuo PC, et al. Dobutamine stress echocardiography for preoperative cardiac risk stratification in patients undergoing orthotopic liver transplantation. *Liver Transpl Surg* 1998;4:253-7.
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-97.
- Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. *Ann Intern Med* 1993;118:81-90.
- Morise AP, Haddad WJ, Beckner D. Development and validation of a clinical score to estimate the probability of coronary artery disease in men and women presenting with suspected coronary disease. *Am J Med* 1997;102:350-6.
- Gibbons RJ, Antman EM, Alpert JS, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). *J Am Coll Cardiol* 2002;40:1531-40.
- Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). *J Am Coll Cardiol* 2003;41:159-68.

22. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. *N Engl J Med* 1979;300:1350-8.
23. Pryor DB, Harrell FE Jr, Lee KL, et al. Estimating the likelihood of significant coronary artery disease. *Am J Med* 1983;75:771-80.
24. Ward RP, Mansour IN, Lemieux N, et al. Prospective evaluation of the clinical application of the American College of Cardiology Foundation/American Society of Echocardiography appropriateness criteria for transthoracic echocardiography. *J Am Coll Cardiol Img* 2008;1:663-71.
25. Martin NM, Picard MH. Use and appropriateness of transthoracic echocardiography in an academic medical center: a pilot observational study. *J Am Soc Echocardiogr* 2009;22:48-52.
26. Kirkpatrick JN, Ky B, Rahmouni HW, et al. Application of appropriateness criteria in outpatient transthoracic echocardiography. *J Am Soc Echocardiogr* 2009;22:53-9.
27. Willens HJ, Gomez-Marin O, Heldman A, et al. Adherence to appropriateness criteria for transthoracic echocardiography: comparisons between a regional Department of Veterans Affairs health care system and academic practice and between physicians and mid-level providers. *J Am Soc Echocardiogr* 2009;22:793-9.
28. Ward RP, Krauss D, Mansour IN, et al. Comparison of the clinical application of the American College of Cardiology Foundation/American Society of Echocardiography appropriateness criteria for outpatient transthoracic echocardiography in academic and community practice settings. *J Am Soc Echocardiogr* 2009;22:1375-81.
29. Rao G, Sajjani N, Kusnetzky LL, Main ML. Appropriate use of transthoracic echocardiography. *Am J Cardiol* 2010;105:1640-2.
30. Rao GA, Sajjani NV, Kusnetzky LL, Main ML. Appropriate utilization of transesophageal echocardiography. *Am J Cardiol* 2009;103:727-9.
31. Mansour IN, Lang RM, Furlong KT, et al. Evaluation of the application of the ACCF/ASE appropriateness criteria for transesophageal echocardiography in an academic medical center. *J Am Soc Echocardiogr* 2009;22:517-22.
32. Aggarwal NR, Wuthiaropas P, Karon BL, et al. Application of the appropriateness criteria for echocardiography in an academic medical center. *J Am Soc Echocardiogr* 2010;23:267-74.
33. McCully RB, Pellikka PA, Hodge DO, et al. Applicability of appropriateness criteria for stress imaging: similarities and differences between stress echocardiography and single-photon emission computed tomography myocardial perfusion imaging criteria. *Circ Cardiovasc Imaging* 2009;2:213-8.
34. Mansour IM, Lang RM, Aburuwaida WM, et al. Evaluation of the application of the ACCF/ASE appropriateness criteria for stress echocardiography. *J Am Soc Echocardiogr* 2010;23:1199-204.
35. Sirovich B, Gallagher PM, Wennberg DE, Fisher ES. Discretionary decision making by primary care physicians and the cost of U.S. Health care. *Health Aff (Millwood)* 2008;27:813-23.
36. Zuckerman S, Waidmann T, Berenson R, Hadley J. Clarifying sources of geographic differences in Medicare spending. *N Engl J Med* 2010;363:54-62.
37. Warnes CA, Williams RG, Bashore TM, et al. ACCF/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). *J Am Coll Cardiol* 2008;52:e1-121.
38. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. *J Am Coll Cardiol* 2010;55: e27-129.
39. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA* 2009;301:1547-55.
40. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2009;53:e1-90.
41. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. *Circulation* 2010;121:1768-77.
42. Physician Consortium for Performance Improvement (PCPI) Position Statement. The Evidence Base Required for Measures Development. Chicago, IL: American Medical Association; 2009.
43. Douglas P, Iskandrian AE, Krumholz HM, et al. Achieving quality in cardiovascular imaging: proceedings from the American College of Cardiology-Duke University Medical Center Think Tank on Quality in Cardiovascular Imaging. *J Am Coll Cardiol* 2006;48:2141-51.
44. The Intersocietal Accreditation Commission. <http://www.intersocietal.org/icael/apply/standards.htm>. Accessed June 10, 2010
45. Diamond GA. A clinically relevant classification of chest discomfort. *J Am Coll Cardiol* 1983;1:574-5.
46. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). *J Am Coll Cardiol* 2004;44:671-719.
47. Campeau L. Letter: grading of angina pectoris. *Circulation* 1976;54:522-3.
48. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. *JAMA* 2000;284:835-42.